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ABSTRACT 
Background 
 
The inflammatory bowel diseases (IBDs), Crohn’s disease (CD), ulcerative 
colitis (UC), and inflammatory bowel disease unclassified (IBDU) are chronic 
inflammatory conditions of the gastrointestinal tract characterized by 
remissions and exacerbations. Recently, the therapeutic targets have aimed 
towards mucosal healing (MH), which is associated with less hospitalization 
and surgery and also with better quality of life. Moreover, during the era of 
TNFα-blocking therapy, deep remission (DR), meaning clinical remission 
with MH, has been the most desirable target for therapy in IBD. We 
constructed a study to evaluate how often patients on TNFα-blocking 
maintenance therapy actually achieve DR and also to evaluate the disease 
course, predictive factors, impact of histological remission on relapse risk, 
and response to retreatment in patients with IBD in DR after cessation of 
TNFα-blocking therapy. Fecal calprotectin (FC) concentration has been 
shown to be a useful surrogate marker for MH during TNFα-blocking 
therapy in IBD, and high FC levels seem to indicate a risk of IBD relapse 
during clinical remission. Our aim was to evaluate whether a normal FC after 
induction therapy with TNFα-blocking agents predicts the outcome of IBD 
patients during maintenance therapy and whether elevated FC concentration 
after ceccation of TNFα-blocking therapy can predict clinical or endoscopic 
relapse in asymptomatic patients.  
 
Patients and methods  
 
To evaluate the achievement of DR in Study II, data were collected 
retrospectively at eight gastroenterological units in various parts of Finland 
for all UC, CD, and IBDU patients treated with scheduled TNFα-blocking 
therapy for at least 11 months, after which they underwent an 
ileocolonoscopy during 2010 and 2011. A total of 252 patients with IBD (183 
patients with CD, 62 with UC, and 7 with IBDU) were recruited. At the time 
of ileocolonoscopies, clinical disease activity was assessed by physicians’ 
global assessment (PGA) scores and endoscopic activity in CD by the simple 
endoscopic score for Crohn’s disease (SES-CD), and in UC and IBDU by the 
Mayo endoscopic score. To evaluate histological activity, biopsies were taken 
from the most severely affected areas during ileocolonoscopies, and findings 
were graded as normal or active inflammation. 
 
Prospective, multicenter Studies III and IV explored the relapse rate, 
predictive factors, impact of histological remission on relapse risk, response 
to retreatment, and capacity of FC to predict relapse in IBD patients in DR 
after discontinuing TNFα-blocking therapy. These studies included 52 
patients (17 CD, 30 UC, 5 IBDU) in clinical, endoscopic, and FC-based 
remission after at least one year of TNFα-blocking therapy. Patients were 
recruited between February 2010 and June 2012 at nine gastroenterological 
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units. Clinical and endoscopic remission and relapse were defined according 
to the Harvey-Bradshaw index (HBI) and SES-CD in CD and Mayo score in 
UC and IBDU. After discontinuing TNFα-blocking therapy, all patients were 
followed up with clinical assessment and blood tests every four weeks for six 
months and thereafter every second month up to 12 months or until the 
relapse. Endoscopic and histological assessment of disease activity was 
performed at 4 and 12 months and at relapse. In the event of a clinical 
relapse with endoscopically active disease or minor clinical symptoms, but 
severe endoscopic relapse, TNFα-blocking therapy was reinitiated. Patients 
were asked to provide a stool sample for FC measurement prior to every visit 
and to fill out questionnaires on quality of life at baseline, at time of 
ileocolonoscopies, and at relapse. 
 
Study I was constructed to evaluate the predictive value of FC measurement 
after induction of TNFα-blocking therapy. This study comprised 60 IBD 
patients (34 CD and 26 UC), who were treated for active luminal disease and 
had an elevated FC level at baseline and a documented FC concentration 
after induction with TNFα-blocking agonists. After the induction therapy, 
patients were divided into two groups according to the postinduction FC 
level. Clinical disease activity was assessed with HBI in CD and with partial 
Mayo score in UC at baseline, after induction with TNFα-blocking agonists, 
and at one year. 
  
Results 
 
Among 252 patients receiving TNFα-blocking maintenance therapy, 67% 
were in clinical remission and 48% in DR at the time of ileocolonoscopy 
(Study II). Clinical remission was achieved in 63% of CD patients and 75% 
of UC patients, whereas DR was achieved in 43% of CD patients and 62% of 
UC patients. No significant difference in achieving clinical remission 
emerged between CD and UC patients (p = 0.072), but DR was significantly 
more common in UC patients than in CD patients (p = 0.007). In this study, 
FC measurements were available for 163 patients at the time of 
ileocolonoscopy. Median FC level was significantly lower in patients in DR 
than in the others (50 μg/g, range 1–722 vs. 288 μg/g, range 6–4190, p < 
0.0001). 
 
When exploring the outcome after cessation of TNFα-blocking therapy 
(Study III), 33% patients relapsed after a median follow-up time of 13 
(range 12-15) months. Ten patients experienced clinical and endoscopic 
relapse, five patients clinical relapse with mild endoscopic activity, and two 
CD patients severe endoscopic relapse. The relapse rate was equal in both CD 
and UC (p = 0.896). Based on univariate analysis, no specific predictive 
factors were associated with the relapse. Reassuringly, the retreatment with 
TNFα-blocking agents was effective in 94% of patients. 
 
In Study I, the FC cut-off value of 139 µg/g was optimized as the best cut-off 
for predicting one-year clinical relapse, with a sensitivity of 72% and a 
specificity of 80% (AUC 0.838 (0.724–0.952)). Smoking (OR 1.19, 95% CI 
4.32–0.33, p = 1), gender (OR 0.33; 95% CI 0.11–1.00, p = 0.064), or chosen 
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TNFα-blocking agents (OR 0.35; 95% CI 0.10–1.23, p = 0.147) did not 
significantly affect the outcome. An FC decline of more than 88% during 
TNFα-blocking induction therapy predicted clinical remission with a 
sensitivity of 87% and, a specificity of 65% (AUC 0.771 (0.652–0.890), p 
<0.001). After discontinuing TNFα-blocking therapy, patients relapsing 
showed constantly elevated FC levels for a median of 94 (13–317) days before 
the relapse (Study IV). FC levels were significantly higher thanlevels at 
baseline two (p = 0.0014), four (p = 0.0056), and six (p = 0.0029) months 
before endoscopic relapse. More importantly, once FC was found to be 
elevated, it remained elevated until the relapse. Constantly normal FC 
concentrations or only transiently elevated FC concentrations during the 
follow-up were highly predictive for clinical and endoscopic remission. 
Normal FC concentrations in patients with remission were associated with 
histological remission. Mild or moderate histological inflammation at the 
time of cessation of TNFα-blocking therapy did not have an impact on 
relapse risk.  
 
Conclusions 
 
DR is achievable in up to half of IBD patients on TNFα-blocking maintenance 
therapy in everyday clinical practice. A concomitant histological remission is 
achievable relatively often. Despite achieving DR, discontinuing TNFα-
blocking therapy was considered reasonable for only about half of our 
patients. When TNFα-blocking therapy was ceased in IBD patients in DR, up 
to 67% remained in clinical remission during the 12-month follow-up. 
Moreover, the majority of these patients also remained in endoscopic 
remission. In relapsers, the response to restart of TNFα-blocking agonist 
appeared effective and well tolerated. A normal FC after TNFα-blocking 
induction therapy predicts sustained clinical remission in the majority of 
patients with active luminal disease with scheduled treatment, and it may 
also predict endoscopic remission. In addition, FC seems to be a useful 
surrogate marker for predicting relapse in patients with IBD and identifying 
patients requiring a close follow-up in clinical practice. 
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INTRODUCTION 
Inflammatory bowel diseases (IBDs), including Crohn’s disease (CD) 
ulcerative colitis (UC), and inflammatory bowel disease unclassified (IBDU), 
are chronic idiopathic inflammatory disorders affecting the gastrointestinal 
tract (Abraham et al. 2009). While UC and IBDU affect only the colon, CD 
may affect the whole gastrointestinal tract. The etiology and pathogenesis of 
these conditions remain somewhat obscure. The most widely accepted 
hypothesis is that these conditions arise from interactions between 
immunoregulatory, genetic, and environmental factors. In IBD, bowel 
damage is induced by an uncontrolled activation of both innate and adaptive 
immunity due to an imbalance between pro-inflammatory cytokines. The 
natural history of IBD is characterized by repeated episodes of inflammation 
and ulceration of the bowel, which may lead to complications that lower the 
quality of life and increase the need for hospitalization, surgery and 
escalation of therapy (Langholz et al. 1999, Peyrin-Birulet et al. 2010). 
 
Treatment decisions for IBD have usually been based on disease severity,  
localization, and extent. Recent years, management of IBD has changed 
markedly, as the tumor necrosis factor alpha (TNFα) antagonists infliximab 
(IFX), adalimumab (ADA), and most recently golimumab (GLM) have 
become available. Earlier, the treatment goal for IBD has been to achieve 
clinical response or remission and normalization of laboratory parameters. 
Recently, mucosal healing (MH) and prevention of extraintestinal 
complications have been regarded as important treatment goals, in managing 
IBD. MH is assessed by endoscopy and is thought to be an important 
prognostic factor for the efficacy of treatment in IBD associated with fewer 
hospitalizations and less surgeries (Lichtenstein et al. 2002, 2004, Schnitzler 
et al. 2009). As endoscopies are time-consuming and unpleasant for 
patients, alternative methods to assess MH have emerged. In IBD, the levels 
of fecal calprotectin (FC), an inflammatory product of the intestinal mucosa, 
correlates closely with endoscopic and histological grading of disease activity 
(Roseth et al. 1999, Sipponen et al. 2008a). A normalized FC level has been 
shown to be a useful predictor of MH in IBD patients, and high FC levels may 
indicate a risk of relapse during clinical remission (Tibble et al. 2000b, Costa 
et al. 2005, D’Inca et al. 2008, Garcia-Sanchez et al. 2010).  
 
TNFα antagonists induce and maintain remission in patients with moderate 
to severe CD (Rutgeerts et al. 2006, Colombel et al. 2007, Rutgeerts et al. 
2012) and UC (Rutgeerts et al. 2005, Sandborn et al. 2012a). Although TNFα 
-blocking therapy has been used in clinical practice for over a decade, scant 
data have appeared on the prevalence of concomitant clinical remission and 
MH during maintenance therapy with anti-TNFα agents. This information is 
essential when considering the possibility of discontinuation of TNFα-
blocking therapy in IBD patients. In clinical practice, the decision on whether 
to continue or discontinue TNFα-blocking therapy in IBD patients in DR is 
still based on assessment of the patient’s individual risks and benefits. 
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Existing guidelines have concluded that due to limited evidence no 
recommendations can be made on when and in whom to discontinue TNFα-
blocking therapy after having achieved clinical remission (Dignass et al. 
2010, D’Haens et al. 2011, Dignass et al. 2012a). This and the chronic nature 
of IBD may lead to long-term maintenance therapy with TNFα antagonists, 
raising questions about safety and economic issues. A few studies, mainly on 
CD, have been published on the duration of remission after discontinuation 
of TNFα-blocking therapy, and potential risk factors for relapse (Waugh et al. 
2010, Louis et al. 2012, Steenholdt et al. 2012, Molnar et al .2013, Rismo et 
al. 2013, Farkas et al. 2013). None of these studies have assessed endoscopic 
activity during the follow-up, nor have they determinated the optimal 
monitoring strategy after discontinuation of TNFα-blocking therapy. 
 
The objective of this thesis was to establish how often DR can be achieved in 
IBD patients on TNFα-blocking therapy in everyday clinical practice and to 
assess the relapse rate and predictive factors of relapse after cessation of 
maintenance therapy with TNFα-blocking agents in IBD patients in DR. 
Additionally, this thesis aimed to evaluate the role of FC in predicting long-
term response to TNFα-blocking therapy and its capacity to predict a clinical 
or endoscopic relapse after discontinuation of TNFα-blocking therapy.  
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REVIEW OF THE LITERATURE 
The first description of IBD was provided by British physician Samuel Wilks 
in 1895, who recognized UC from bacterial dysentery, and also described a 
case report of a woman with a transmural inflammation of the colon and 
terminal ileum, resembling ileoceacal CD (Kirsner 1988). CD, also known as 
terminal ileitis, regional enteritis, granulomatous ileitis, hyperplastic ileitis, 
chronic interstitial enteritis, and chronic ulcerative ileitis, was first described 
by Polish surgeon Antoni Leśniowski in 1904. Nonetheless, CD is named 
after an American gastroenterologist Burrill Crohn, who described fourteen 
patient cases with regional enteritis in 1932, and later that year published the 
case series as "Regional ileitis: a pathologic and clinical entity” with his 
colleagues Leon Ginzburg and Gordon Oppenheimer (Crohn et al. 1932).  
 
CD is a chronic transmural inflammatory disease of the gastrointestinal (GI) 
tract that can affect any part of the GI tract. CD is commonly associated such 
complications as abscesses, fistulas, and strictures. Unlike CD, UC is a 
nontransmural inflammatory disease that is restricted to the colon. Both 
conditions are characterized by phases of remission and episodes of relapse. 
In some patients the disease may be chronically active, meaning a 
continuously active inflammation of the gut (Baumgart and Sandborn 2007).  
 
 
1 Etiology and pathogenesis of inflammatory bowel disease 
 
Although knowledge of immunological mechanisms has improved greatly in 
recent years, the etiology of IBD remains largely unknown. Research 
indicates that an individual’s genetic susceptibility, external environment, 
intestinal microbial flora, and immune responses are all involved and 
functionally integrated in the pathogenesis of IBD (Danese et al. 2006). 
 
1.1 Genetics 
 
A positive family history is the single greatest risk factor for IBD. In 
population-based studies, the proportion of IBD patients having a positive 
family history varies from 2% to 20% (Gaya et al. 2006). The pooled 
concordance in monozygotic twins has also been demonstrated to be 36% 
(Rosenstiel et al. 2009). Evidence also suggests ethnic aggregation of IBD, 
with higher rates of IBD among Jewish people than in any other ethnic 
group. The modern era of IBD genetic research began in 2001 with the 
discovery of encoding caspase-activating recruitment domain 15 (CARD15), 
also known as nucleotide-binding oligomerization domain 2 (NOD2), the 
first susceptibility gene for CD (Ogura et al. 2001). The NOD2 gene codes for 
a protein that was originally described as an intracellular receptor 
recognizing the muramyl dipeptide (MDP), a conserved motif present in 
peptidoglycan from both Gram-positive and -negative bacteria (Inohara et al. 
2003). MDP stimulation induces autophagy, which controls bacterial 
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replication and antigen presentation and modulates both innate and adaptive 
immune responses (Cooney et al. 2010, Travassos et al. 2010). Mutations of 
this gene are strongly associated with CD affecting ileum and with stricturing 
CD (Gaya et al. 2006). CARD15/NOD2 seems to also be a disease-modifier 
gene for CD. Furthermore, the Th17 and IL-23 pathway is well established in 
the pathogenesis of IBD, with susceptibility gene loci IL23R, IL12B, JAK2, 
and STAT3 having been identified in both UC and CD (Anderson et al 2011, 
Brand et al 2009). Defects in the function of IL-10 have also been associated 
with CD and UC (Tremelling et al. 2007). Moreover, genetic analyses have 
shown an indispensable role for autophagy in immune responses in IBD and 
have reported two autophagy-related genes, ATG16L1 and IRGM (Rioux et 
al. 2007, Hampe et al. 2007, McCarroll et al. 2008). Recent studies have 
brought the number of IBD-associated gene loci to 163, of which 110 are 
associated with both diseases, 30 are CD-specific and 23 are UC-specific 
(Jostins et al. 2012). 
 
1.2 Environmental factors 
 
There is no doubt that several environmental factors, such as smoking, diet, 
viruses, bacteria, drugs, especially nonsteroidal anti-inflammatory drugs 
(NSAIDs), geography, social stress, and a psychological component, play 
important roles in the pathogenesis of IBD. Among these risk factors, 
smoking remains the most widely studied and documented (Cosnes 2004, 
Mahid et al. 2006, Lakatos et al. 2007, Higuchi et al. 2012, Lakatos et al. 
2013). Smoking increases the risk of developing CD and worsens its course, 
raising exacerbation rates and the need for steroids and 
immunosuppressants and promoting complications and reoperations 
(Cosnes et al. 2002, Johnson et al. 2005). Contrary to its effect on CD, 
subsequent studies have confirmed the protective effect of heavy smoking on 
the development of UC-related relapses (Cosnes 2004). Diet has been 
hypothesized to play an important role in the pathogenesis of IBD. The 
dietary factors that most likely affect IBD development are fat, 
carbohydrates, macrononutrients, and protein, in particular saturated fatty 
acids, fiber, omega-3 and omega-6 fatty acids and refined sugar (Cruber et al. 
2012). High intakes of fat, polyunsaturated fatty acids, omega-6 fatty acids, 
and meat have been shown to increase the risk of CD and UC, while high 
intakes of fruits and fiber decrease CD risk, and a high intake of vegetables 
decreases the risk of UC (Hou et al. 2011). Vitamin deficiencies in general 
and vitamin D deficiency in particular often occur in patients with IBD 
(Andreassen et al. 1997). Bendix-Struve and co-workers (2010) 
demonstrated that vitamin D3 modifies T-cell proliferation and increases IL-
6 levels in CD patients, hence having an impact on the pathogenesis of CD.  
 
1.3 Immune response 
 
Available evidence suggests that dysfunctions of the innate and adaptive 
immune pathways contribute to the aberrant intestinal inflammatory 
response in patients with IBD. The innate immune system is responsible for 
the early immune response, providing a nonspecific, rapid defence against 
pathogens with monocytes, macrophages, neutrophils, dendritic cells, 
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natural killer (NK) cells, and the complement system (Medzhitov and 
Janeway 2000). This innate immune system is inborn and not tailored to any 
particular immunological challenge. This form of immunity is initiated by the 
recognition of microbial antigens, which is provided by pattern-recognition 
receptors (PRRs), including membrane-associated toll-like receptors (TLRs) 
on the cell surface and NOD-like receptors in the cytoplasm (Abreu et al. 
2005). Studies have demonstrated that the behavior of the cells mediating 
innate immunity and the expression and function of both TLRs and NOD 
proteins are altered significantly in individuals with IBD (Bonen et al. 2003, 
Abraham and Cho 2006). 
 
The adaptive – recognized also as the specific – immune system is slower and 
tailored by T- and B-lymphocytes. Over the past years, most studies have 
focused on the role of abnormal adaptive immune responses in the 
pathogenesis of IBD. CD and UC represent clearly distinct forms of gut 
inflammation; CD has long been considered to be driven by a Th1 response, 
and UC has been associated with a nonconventional Th2 response (Cobrin et 
al. 2005, Targan et al. 2005). Most recently, also Th17 cells, regulated by IL-
23, have been shown to be involved in the gut inflammatory response in IBD 
(Geremia et al. 2012). The activation of Th1 and Th17 cells in CD provides 
abundant interleukins (ILs), and transforming growth factor β by antigen 
presenting cells and macrophages. These cells increase the secretion of the 
pro-inflammatory cytokines IL-2, IL-17, interferon (IFN) -γ, and TNFα, 
leading to intestinal inflammation. The cytokines, in turn, feed into a self-
sufficient cycle and stimulate antigen-presenting cells, macrophages, 
fibroblasts, and endothelial cells to produce TNFα, IL-1, IL-6, IL-8, IL-12, 
and IL-18 (Collison et al. 2010, Engel and Neurath 2010, Franke et al. 2010). 
On contrast, in UC, atypical NK T-cells release higher amounts of the Th2 
cytokine IL-13 than T-cells from controls or CD patients (Heller et al. 2005). 
In addition, defects in regulatory T-cell function and in T-cell apoptosis may 
occur (Brown and Mayer 2007).  
1.4 Microbiota 
 
The whole human gut microbiome consists of approximately 1150 bacterial 
species, with each individual host having approximately 160 species (Qin et 
al. 2010). The gut microbiome is established within the first two weeks of life 
and thereafter usually remains remarkably stable. The GI microbiome of 
healthy humans is dominated by four major bacterial phyla: Firmicutes, 
Bacteroidetes, Proteobacteria, and Actinobacteria (Morgan et al. 2012). 
Some studies examing the gut flora in CD and UC in both inflamed and 
noninflamed segments have found a significantly reduced biodiversity in the 
fecal microbiome of IBD patients relative to healthy controls (Joossens et al. 
2011). Other studies have described the microbiota as more unstable in IBD 
patients than in healthy individuals (Andoh et al. 2011). In IBD patients the 
microbiota is characterized by a relative lack of Firmicutes and Bacteroidetes, 
and an overrepresentation of enterobacteria (Sartor 2008). Also a reduction 
in Clostridium spp. and an increase in Escherichia coli, especially an 
 18 
 
adherent and invasive E. coli (AIEC), invasive Fusobacterium nucleatum, 
and mucolytic bacteria such as Ruminococcus gnavus and Ruminococcus 
torques and Mycobacterium avium paratuberculosis (MAP) have been 
reported in IBD (Martinez et al. 2008, Feller et al. 2007, Khor et al. 2011). 
However, the role of MAP in IBD pathogenesis remains obscure (Bull et al. 
2003). Patients with IBD have a compromised mucus layer and an epithelial 
surface that is densely coated with bacteria; the abundant presence of 
Ruminococcus strains in IBD mucosa raises the possibility that such 
microbes may contribute to the barrier defect observed in IBD, although 
whether their presence is causal or correlative is unclear (Khor et al. 2011). 
 
 
2 Epidemiology 
 
A north–south gradient in Europe exists, with higher incidence rates of IBD 
in northern countries, but the incidence in southern and eastern Europe is 
increasing (Burisch et al. 2013). Recently, the prevalence of UC seems to be 
decreasing, whereas the prevalence of CD is increasing due to earlier onset of 
the disease and a low mortality rate (Loftus et al. 2007). The highest 
incidence and prevalence rates can be found in developed and modernized 
countries, with annual incidence of up to 16.3/100,000 and prevalence of 
213/100,000 (Loftus 2004, Baumgart and Carding 2007, Bernstein and 
Shanahan 2008). In a recent European cohort study (EccoEpiCoM), a very 
high incidence of UC was found on the Faroe Islands, being 31.8/100,000 in 
UC and 83.1/100,000 in IBD (Burisch et al. 2014). In Finland, the prevalence 
of IBD has increased nearly threefold during the past 15 years, being 
291/100,000 for UC and 124/100,000 for CD (Manninen et al. 2010). 
Distinct north-south and west-east gradients exist within Europe, with the 
highest incidence rates in northern and western countries (Burisch et al. 
2014). An increase during the last decade in the incidence of both UC and CD 
has been demonstrated in a Finnish study locally (Manninen et al. 2010), but 
the incidence seems to be more stable nationwide (Jussila et al. 2012).  A 
clear north-south gradient has also been observed (Jussila et al. 2013).  
 
 
3 Disease localization and disease behavior 
 
Typical presentation of CD includes discontinuous involvements of various 
portions of the GI tract from the mouth to the anus and potential 
development of disease complications such as abscesses, fistulae, or 
strictures. Typically, at diagnosis, about one-quarter of patients have both 
ileal and colonic disease, another quarter have only colonic disease, and 
about half have only terminal ileitis. Less than 10% of CD patients have ileal 
involvements out of reach of ileocolonoscopy or involvements in the 
proximal small bowel or upper GI tract (Baumgart and Sandborn 2007). 
Localization of the disease remains exceedingly stable over time, but the 
disease behavior may change, typically from inflammatory to stricturing or 
penetrating (Louis et al. 2001, Cosnes et al. 2002). Patients with ileal CD are 
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more likely to develop stricturing complications, and those with perianal 
lesions penetrating complications (Cosnes et al. 2002). The 2005 Montreal 
revision of the Vienna classification differentiates the age at onset (A: A1 ≤ 16 
years, A2: 17-40 years, A3 > 40 years), disease localisation (L1: ileal, L2: 
colonic, L3: ileocolonic, L4: isolated upper disease), and diseasebehavior (B1: 
nonstricturing, nonpenetrating, B2: stricturing, B3: penetrating, p: perianal 
disease modifier) of CD and is regarded as the international standard of CD 
phenotype subtyping (Gasche et al. 2000, Satsangi et al. 2006). 
 
UC tends to begin in the rectum and extend proximally, affecting the bowel 
in a continuous fashion. A classification by the Montreal Working Group 
divides UC into proctitis (E1), left-sided colitis, also known as distal colitis 
(E2), and extensive colitis (E3) and also takes into consideration disease 
behavior and age at onset (Silverberg et al. 2005). Typically, at diagnosis, 40-
50% of patients have proctitis, 30-40% left-sided colitis and up to 25-30% 
pancolitis (Conrad et al. 2014). Disease can progress and spread over time. 
Left-sided colitis or proctitis may extend to pancolitis in up to 53% of 
patients (Moum et al. 1999). Although UC is restricted to the colon by 
definition, nonspecific mucosal inflammation in the terminal ileum 
(“backwash ileitis”) is found in 10–20% of UC patients (Conrad et al. 2014). 
 
 
4 Diagnosis 
 
No single test for diagnosis of IBD exists. In 1997, Lennard-Jones and 
Shivananda defined widely accepted macroscopic and microscopic criteria 
for diagnosing IBD. Macroscopic tools include physical, endoscopic, and 
radiological examination, and less frequently, examination of surgical 
specimens. In CD, the diagnosis is based on noncontinuous and often 
granulomatous inflammation of the gut, while in UC the inflammation is 
typically continuous with a decreasing gradient of inflammation from the 
distal to the proximal colon. Diagnosis is currently based on a combination of 
clinical presentation, endoscopic features, histological findings, radiological 
manifestations, surgical findings, and serological abnormalities (Van Assche 
et al. 2010a, Dignass et al. 2012b). In 5–10% of IBD patients, no definite 
diagnosis of CD or UC can be made when only the colon is affected. For these 
particular cases the term “inflammatory bowel disease unclassified” (IBDU) 
is used (Satsangi et al. 2006). The term “indeterminate colitis” refers to a 
pathological-anatomical diagnosis describing a colectomy specimen with 
overlapping features of CD and UC (Price 1978, Satsangi et al. 2006).  
 
4.1 Clinical presentation 
 
Clinical presentation of CD. A heterogeneity of manifestations, a potentially 
insidious onset, the presence of overlapping features with other IBD, and a 
presentation without GI symptoms, can make diagnosis of CD extremely 
difficult. Chronic or nocturnal diarrhea is the most common symptom of CD, 
affecting up to 85% of patients (Sands 2004). Abdominal pain occurs in 
approximately 70% and weight loss in 60% of patients. In colonic CD, bloody 
and/or mucous stools occur in about half of patients (Lennard-Jones and 
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Shivananda 1997). Fever, rectal bleeding and fatigue may also present. 
Approximately 75% of patients with large bowel CD develop perianal 
pathology, including skin tags, deep ulcers, fissures, fistulae, abscesses, blind 
sinus tracts, and strictures at some point during the disease course (Warren 
2004). Clinical signs also include pallor, cachexia, an abdominal mass or 
tenderness, and aphthous ulcers in the oral cavity. Associated extraintestinal 
features may include peripheral arthopathy, axial arthritis, uveitis, 
episcleritis, erythema nodosum, pyoderma gangrenosum, or hepatobiliary 
disease such as primary sclerosing cholangitis. Extraintestinal manifestations 
are most common in colonic CD (Van Assche et al. 2010a). In children, 
anemia, fever, failure of growth, or delayed development of secondary sex 
characteristics may be observed (Langholz et al 1997). Although the onset is 
typically insidious, occasionally CD presents in a fulminant manner at its 
onset or with the presence of toxic megacolon (Swan et al. 1998). 
 
Clinical presentation of UC. Clinically, UC is characterized by loose stool or 
diarrhea and chronic abdominal pain. Patients with active disease also 
present with rectal urgency, tenesmi, mucus or blood in stool, nocturnal and 
postprandial defecation, or even constipation (Lennard-Jones and 
Shivananda 1997, Dignass et al. 2012b). The clinical picture mainly depends 
on the extent of bowel involvement, disease activity, and extraintestinal 
manifestations and complications. Inflammatory arthropathies and primary 
sclerosing cholangitis (PSC) are the most common and important 
extraintestinal manifestations in UC. PSC is diagnosed in about 2–10% of UC 
patients and occurs occasionally with autoimmune hepatitis (overlap 
syndrome). As in CD, other extraintestinal manifestations involve skin 
(erythema nodosum, pyoderma gangrenosum), eyes (episcleritis, uveitis), 
and bones (osteoporosis) (Van Assche et al. 2013). 
 
4.2. Laboratory findings 
 
Laboratory features are not specific markers for IBD. They detect 
inflammatory processes (elevated erythrocyte sedimentation rate [ESR], C-
reactive protein [CRP], FC) or deficiencies due to malnutrition (iron 
deficiency, anemia) and may help to assess disease activity as well as 
complications. Anemia and thrombocytosis are the most common changes 
seen in IBD patients, especially in CD. In addition, ESR and CRP may be 
elevated and albumin reduced. Stool testing for pathogenic bacteria, 
particulary Clostridium difficile, and other parasites is necessary to exclude 
infectious colitis. The most frequently studied serological markers in IBD are 
antineutrophil-cytoplasmic antibodies (ANCA), directed against Candida 
albicans, and antibodies against mannan of Saccharomyces cerevisiae 
(ASCA). Perinuclear (pANCA) or atypical ANCA (xANCA) can be found in 
50–70% of UC patients and in less than 10% of CD patients. ANCA positivity 
and a negative test for ASCA are more likely to indicate UC than CD (Conrad 
et al. 2002). In patients with IBDU, combined determination of ANCA and 
ASCA may provide a definitive diagnosis. Another serological marker, 
specific for UC, is anti-goblet cell antibodies (GAB), occurring in 15–28% of 
UC patients. In an ideal setting, GAB is highly specific for UC (Conrad et al. 
2006). Furthermore, antibody responses towards E. coli outer membrane 
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porin C (anti-ompC), a CD-related bacterial sequence from Pseudomonas 
fluorescens (anti-12), and towards a flagellin CBir1 (anti-CBir1) are seen in 
approximately half of CD patients and only about 10% of UC patients (Mow 
et al. 2004). Anti-CBir1 expression has been shown to be associated with 
small bowel disease as well as with penetrating and stricturing disease 
(Vernier et al. 2004). These antibody responses may play a role in subtyping 
IBD patients or in predicting disease course, but because of their inaccuracy, 
these tests are of little use in clinical practice and have limited value in 
monitoring disease activity.  
 
4.3 Endoscopy 
 
Endoscopy plays an essential role in the diagnosis, management, prognosis, 
and surveillance of IBD. Initial endoscopy should intubate the terminal 
ileum, and in clinical practice this is achieved in approximately 85% of 
ileocolonoscopies. During the endoscopy multiple biopsy specimens should 
be taken from all segments of the bowel. CD is characterized by a 
discontinuous and ulcerous transmural inflammation, often involving the 
ileocaecal region, but can be detected in the whole digestive tract, typically 
with the involvement of the terminal ileum and cecum. Small, deep aphthous 
ulcers or longitudinal ulcers, anal lesions, and a cobblestone appearance of 
the ileum are the most common features of CD (Nikolaus and Schreiber 
2007). By contrast, UC typically presents with continuous, uniform 
inflammation that extends proximally from the rectum. The line between 
inflamed and normal areas is usually clear and may occur abruptly, especially 
in distal disease. Occasionally, in total colitis a “backwash” ileitis occurs. In 
children, rectal sparing has been described prior to treatment, whereas in 
adults this is more likely due to a topical treatment (Rajwal et al. 2004, Odze 
et al. 1993). In severe, active colitis ileocolonoscopy may lead to an increased 
risk of bowel perforation, and therefore, flexible sigmoideoscopy may 
bepreferred, with ileocolonoscopy reserved for later use (Van Assche et al. 
2010a). Surveillance colonoscopies can be improved by spraying dyes that 
highlight subtle changes in the architecture of the colonic mucosa. 
Chromoendoscopy enhances mucosal detail and submucosal vascular pattern 
and aids in discriminating between neoplastic and non-neoplastic changes, 
based on surface crypt architecture (pit pattern). Chromoendoscopy has a 
sensitivity of 83.3% and a specificity of 91.3% in detecting intraepithelial 
neoplasia (Wu et al. 2012). However, endoscopies are time-consuming, 
expensive, require bowel preparation, and are unpleasant for patients.   
 
In adult IBD, no specific recommendations for esophagogastroduodenoscopy 
(EGD) exist, but it is often performed only on patients with upper GI 
symptoms, like dyspepsia or abdominal pain. However, some experts suggest 
that it should be performed at least once on all newly diagnosed CD patients 
(Hommes and van Deventer 2004). By contrast, EGD is mandatory in 
pediatric IBD patients with growth failure problems, to differentiate between 
UC and CD and to confirm a diagnosis of CD (Castellaneta et al. 2004, 
Crocco et al. 2012). 
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Earlier, only radiographical techniques were available for examinations of 
the entire small bowel. Recently, small bowel wireless capsule endoscopy 
(WCE), magnetic resonance enterography (MRE) and double-balloon 
enteroscopy (DBE) have made it possible to examine the entire small bowel.  
WCE is a device-assisted enteroscopy, which has been designed to examine 
the entire small bowel and to visualize mucosal inflammation. This novel 
technique is useful in assessment of the extent and severity of small bowel 
CD as well as distinguishing between patients with CD and UC. In clinical 
practice WCE has replaced conventional radiology (small bowel follow-
through; SBFT), barium enteroclysis (SBE), computed tomography (CT), and 
push enteroscopy in estimating disease extent, but it is still limited by its cost 
and inability to provide tissue samples or therapy. In patients with 
established CD, the risk of small bowel capsule retention is increased, 
particularly in those with a history of obstructive symptoms or known 
intestinal stenosis (Hoog et al. 2012). Therefore, contraindications for WCE 
are suspected or diagnosed intestinal stenosis or obstruction.  DBE is a 
device-assisted enteroscopy technique for reaching lesions throughout the 
entire small bowel (Yamamoto et al. 2001). The scope may be inserted orally 
or anally depending on which segment of small bowel needs to be examined.  
The advantages of DBE compared with SBE include the evaluation of atypical 
lesions, the ability to obtain biopsies for histopathology, and the potential for 
therapeutic intervention. To date, however, the availability of DBE has been 
limited, and it should be reserved for situations in which tissue samples are 
mandatory or dilatations of strictures are required.   
 
4.4 Radiological techniques 
 
Current imaging standards to examine the small bowel comprise computed 
tomography (CT) and magnetic resonance enterography (MRE). Both 
techniques can determine disease activity and extension based on wall 
thickness and increased intravenous contrast enhancement. Because of the 
increased cancer risk by ionizing radiation later in life, CT is not suitable for 
repeated use, and conventional radiology or CT should be replaced by 
alternative methods particularly in children. CT and MRE are imaging 
techniques with the highest accuracy for diagnosis of ileal and penetrating 
CD, but for diagnosis of terminal ileitis in CD patients, these techniques are 
inferior to ileocolonoscopy (Horsthuis et al. 2008, Van Assche et al. 2010a). 
In many centers, either magnetic resonance enterography or enterolysis has 
replaced radiation techniques in assessment of CD lesions in the small bowel. 
These procedures provide information on disease activity, localization, and 
extension and detect extramural complications such as abscesses, fistulas, 
and sacroilitis. Importantly, because of an absence of ionizing radiation, 
MRE can be performed repeatedly and is thus suitable for follow-up of CD 
patients. Abdominal ultrasound (US) by an experienced operator may 
provide information on the extent of small bowel or colonic inflammation or 
possible complications. However, high interobserver variability and difficulty 
in visualization of deep bowel segments are significant drawbacks (Van 
Assche et al. 2010a). The use of US in clinical practice in most countries is 
still restricted.  
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4.5 Histology 
 
The histological examination of endoscopic biopsies or surgical specimens 
remains a key step in IBD diagnosis and differential diagnosis, particularly in 
the differentiation of UC from CD and other non-IBD conditions (Van Assche 
et al. 2010a). In the initial ileocolonoscopy, multiple biopsies should be taken 
from each segment of the colon and also from the terminal ileum. In 
approximately 10–20% of patients with UC, the inflammation may extend to 
the terminal ileum (backwash ileitis). The diagnostic value of terminal ileum 
biopsies is highest in patients with known or suspected CD (McHugh et al. 
2007).  
 
In CD, the typical histological findings in mucosal biopsy specimens 
comprise focal crypt architectural abnormalities with the presence of 
lymphocytes or plasma cells, granulomas, and mucin preservation at active 
sites (Jerkins et al. 1997, Van Assche et al. 2010a). The granuloma in CD is 
defined as a collection of epithelioid histiocytes (monocyte/macrophage 
cells). The presence of a granuloma is not a requirement for the diagnosis of 
CD. Additional features frequently present are focal chronic inflammation 
without crypt atrophy, focal cryptitis, aphthoid ulcers, disproportionate 
submucosal inflammation, neural hypertrophy with increased intraepithelial 
lymphocytes, and proximal location of ulceration and architectural distortion 
(Magro et al. 2013). The transmural character of CD inflammation can only 
be visible in surgical specimens. In UC distorted crypt architecture with crypt 
branching and atrophy and an irregular villous architecture are more 
common than in CD (Seldenrijk et al. 1991, Surawicz et al. 1994, Jenkins et 
al. 1997). Typically, the mucosal inflammation is proportionate, but may 
occasionally spread into the superficial part of the submucosa. The 
inflammatory infiltrate is composed of lymphocytes, plasma cells, and 
neutrophils, causing cryptitis, defined as the presence of neutrophils within 
crypt epithelium, and crypt abscesses, defined as the presence of neutrophils 
within crypt lumina.  Crypt abscesses are more common in UC (41%) than in 
CD (19%). Plasma cells are typically observed between the base of the crypts 
and the muscularis mucosae (basal plasmacytosis). This feature is helpful in 
differentiation between a first attack of UC (63%) and infectious colitis (6%), 
but not CD (62%) (Seldenrijk et al. 1991, Schumacher et al. 1994, Surawicz et 
al. 1994). The inflammation may cause mucin depletion of the epithelium, a 
less important diagnostic feature as it can also be found in infectious colitis 
and CD (McCormick et al. 1990, Surawicz et al. 1994). Depending on the 
degree of inflammatory activity the surface may become eroded. Chronic 
features of IBD include Paneth cell metaplasia (especially in left-sided 
colitis), presence of inflammatory pseudopolyps, hypertrophy of the 
muscularis mucosae, and rarely identified submucosal fibrosis (Gramlich et 
al. 2007). Granulomas are not found in biopsies of patients with UC.  
 
 
5 Health-related quality of life (HRQoL) 
 
The concept of “quality of life” describes the general well-being of an 
individual or a society. Assessment of health-related quality of life (HRQoL) 
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may shed light on the chronic illness experience, its effects on health 
outcomes, and the overall effect of a disease on a person’s ability to enjoy life. 
HRQoL measurement helps to identify the most appropriate therapy for 
individuals (Sajid et al. 2008). On the population level HRQoL measurement 
can be used for monitoring overall health and any changes in this, as well as 
the effects of social and health policies. In recent years, HRQoL 
measurement has become an important tool in medical science and is also an 
essential outcome in cost-effectiveness and cost-utility analyses. 
 
There are two main types of HRQoL instruments, generic and disease-
specific. Generic instruments are typically used in comparising health status 
among patients with different health states, conditions, and diseases. 
However, the most important function of these instruments is to enable 
comparisons between populations with different diseases (Cramer et al. 
2002). The most commonly used generic HRQoL instruments are the 
Medical Outcomes Study Short-Form (SF-36), EuroQoL (EQ-5D), Sickness 
Impact Profile (SIP), Nottingham Health Profile (NHP), Psychological 
General Well-Being (PGWB), and 15D. The latter is a standardized and self-
administered measure of HRQoL among adults. The 15D comprises of 15 
dimensions: breathing, mental function, speech (communication), vision, 
mobility, usual activities, vitality, hearing, eating, elimination, sleeping, 
distress, discomfort and symptoms, sexual activity, and depression, each 
rated on a 5-point scale. The 15D score varies from 0 (decreased) to 1 (no 
problems in any dimension) (Sintonen 1994). The most commonly used 
HRQoL instruments in IBD is the Inflammatory Bowel Disease 
Questionnaire (IBDQ), a validated, standardized 32-item questionnaire, 
which has been translated into over 40 languages 
(ip.mcmaster.ca/questionnaires). The questionnaire focuses on four different 
aspects of life: digestive symptoms, social function, emotional status, and 
systemic symptoms, each including 5–12 questions. Responses range from 1 
to 7. A total IBDQ score ranges from 32 to 224, with a higher score indicating 
a better quality of life (Guyatt et al. 1989, Pallis et al. 2004). Other commonly 
used HRQoL instruments in IBD are the Rating Form of IBD Patient 
Concerns (RFIPC) and the Cleveland Clinic IBD Scale.  
 
 
6 Assessment of disease activity 
 
Global disease activity assessment in clinical practice relies on clinical history 
and a combination of clinical, serological, endoscopic, and radiological 
findings. Clinical trials focusing on treatment response and long-term 
outcome have revealed the need for standardized and qualitative disease 
activity indices based on clinical symptoms or findings or their combinations. 
 
6.1 Clinical activity 
 
Various activity indices exist. The score most commonly used in clinical trials 
for CD is the Crohn’s disease activity index (CDAI), which comprises one 
serological (hematocrit) and seven clinical variables (number of liquid stools, 
abdominal pain, general well-being, extraintestinal features, antidiarrheal 
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medication, abdominal mass, and body weight) (Best et al. 1976). CDAI score 
ranges from 0 to approximately 650, with CDAI score < 150 indicating 
inactive disease and CDAI score > 450 severe disease (Sostegni et al. 2003). 
Clinical response, a common endpoint in many clinical trials, is suggested to 
be defined as a reduction of ≥100 CDAI points or in some studies ≥ 70 CDAI 
points (Van Assche et al. 2010a). The CDAI score is not commonly used in 
everyday clinical practice because it is rather complex and time-consuming to 
calculate and necessitates keeping a 7-day diary of symptoms. In addition, it 
is not suitable for patients with extensive ileocolonic resection, stoma, or 
symptoms caused by strictures or fistula (Sostegni et al. 2003). Further, 
endoscopic findings and CDAI score correlate poorly, with CDAI 
underestimating the inflammatory activity detected by endoscopy (Sipponen 
et al. 2008a). For paediatric CD patients, a pediatric Crohn’s disease activity 
index (PCDAI) has been developed (Hyams et al. 1991).  
 
In clinical trials, a simple index of CD activity, better known as the Harvey-
Bradshaw index (HBI), is often used to determine disease activity. It includes 
only symptoms and findings from the previous 24 hours (five variables; 
Table 1) (Harvey and Bradshaw 1980). Clinical remission is often defined as 
HBI ≤4 or <4 and clinical relapse HBI ≥8 (Best 2006, Sandborn et al 2002). 
Other clinical activity indices used in clinical trials are summarized in Table 
2.   
 
The most commonly used activity indices for UC are modifications of 
Truelove and Witt’s criteria known as the Mayo score and the Lichtiger score 
(Truelove and Witts 1955, Lichtiger et al. 1994). The Mayo score is most 
commonly used, and it combines both clinical and endoscopic findings 
(Table 3). Scores range from 0 to 12 points, with a higher score indicating 
more severe disease. Clinical remission is defined as a Mayo score of 0 and 
clinical response as a decrease of ≥ 3 points from baseline (Schroeder et al. 
1987, D’Haens et al. 2007). The noninvasive nine-point Mayo score, known 
as the partial Mayo score, has been found to indicate clinical activity as well 
as the full Mayo scores (Lewis et al. 2008).  
 
 
Table 1. Harvey-Bradshaw Index (HBI). 
 
Variable Description 
A. General well-being  very well=0, slightly below par=1, poor=2,  
very poor=3,  terrible=4 
B. Abdominal pain  none=0, mild=1, moderate=2, severe=3  
C. Number of liquid stools per day 
 
number of stools 
D. Palpable abdominal mass 
 
E. Complications 
no=0, dubious=1, definite=2, definite and tender=3 
 
arthralgia, uveitis, erythema nodosum,  
pyoderma gangraenosum, aphthous ulcers, anal fissure,  
new fistula, abscess (score 0 = no, 1 = yes) 
Harvey RF, Bradshaw JM. A simple index of Crohn’s-disease activity. Lancet 1980;315:514.  
Reprinted with permission from Elsevier 
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Table 2. Clinical activity indices used for Crohn’s disease. 
 
Clinical index Reference Variables rated  
    
CDAI 
Crohn’s Disease Activity  
Index 
Best et al. 1976  diarrhea frequency, abdominal pain, 
general well-being, use of antidiarrheal 
medications, abdominal mass, 
extraintestinal features, hematocrit, weight 
 
 
PCDAI 
Pediatric Crohn’s Disease 
Activity  Index 
 
Hyams et al. 1991  abdominal pain, diarrhea, general well-
being, weight, height, abdominal findings 
mass/tenderness, perirectal disease, 
extraintestinal manifestations, hematocrit, 
erythrocyte sedimentation rate, albumin 
 
 
HBI 
Harvey-Bradshaw Index 
Harvey and Bradshaw  
1980  
diarrhea frequency, abdominal pain, 
general well-being, abdominal mass, 
extraintestinal features 
 
 
van Hees Index 
(Dutch Index) 
 
van Hees et al. 1980 body mass index, abdominal mass, sex, 
temperature, stool consistency, previous 
resection, extraintestinal manifestations,   
s-albumin, erythrocyte sedimentation rate 
 
 
Oxford Index Myren et al. 1984  abdominal pain, diarrhea/blood and 
mucus in stool, perianal involvement, 
fistulae, other complications, abdominal 
mass, tenderness, wasting, temperature, 
hemoglobin 
 
 
Cape Town Index Wright et al. 1985  abdominal pain, stool consistency, well-
being, complications (perianal or systemic), 
fever, abdominal mass, weight, 
temperature, hemoglobin 
 
 
PDAI 
Perianal Disease Activity               
Index 
Irvine 1995  discharge of fistulae, pain/restriction of 
activities, restriction of sexual activity, type 
of perianal disease, degree of induration 
 
 
Short CDAI Thia et al. 2011  abdominal pain, diarrhea frequency, 
general well-being 
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Table 3. Mayo Score (Truelove and Witts 1955). 
Variable Description 
A. Stool frequency (patient diary) 
 
0: normal number of stools for the patient 
1: 1–2 stools more than normal 
2: 3–4 stools more than normal 
3: ≥5 stools more than normal 
 
B. Rectal bleeding (patient diary) 
 
0: no blood seen 
1: streaks of blood with stool less than half the time 
2: obvious blood with stool most of the time 
3: blood alone passed 
 
C. Findings of endoscopy 
 
0: normal or inactive disease 
1: mild disease  
2: moderate disease  
3: severe disease 
 
D. Physician’s Global Assessment 
 
0: normal  
1: mild disease 
2: moderate disease 
3: severe disease 
Partial (clinical) Mayo Score =  A + B + D; Endoscopic Mayo Score = C; Total Mayo Score = A + B + C + D. 
 
 
6.2 Endoscopic activity 
 
6.2.1 Endoscopic scoring in Crohn’s disease 
 
In CD, the most frequently used scores are the Crohn’s disease endoscopic 
index of severity (CDEIS), the simplified index SES-CD (simple endoscopic 
score for Crohn’s disease), and the Rutgeerts score (to evaluate anastomosis 
after ileocolic resection) (Table 4). The CDEIS was developed at the end of 
the 1980’s by the French group d’Etude des Affections Inflammatoires 
digestivesis (Mary and Modigliani 1989). The CDEIS is validated and has 
become the gold standard for the assessment of endoscopic activity of CD. 
However, it is complex and time-consuming, subject to interobserver 
variation, and concentrates on the presence of ulcers, with a range from 0 to 
44 points (Sostegni et al. 2003). The threshold for endoscopic remission has 
been set at CDEIS <6, with other criteria for response (a decrease in CDEIS 
>5), complete endoscopic remission (CDEIS <3), and mucosal healing 
(absence of ulcers). The complexity of CDEIS makes it unsuitable for clinical 
practice. It also correlates poorly with clinical activity (Cellier et al. 1994).   
 
To simplify endoscopic assessment, a simple endoscopic score for Crohn’s 
disease (SES-CD) has been developed and validated more than 10 years ago 
(Dapero et al 2002). It is easier and faster to calculate and is therefore more 
suitable for clinical practice. It is known to correlate well with CDEIS. SES-
CD is based on four variables scored in the five ileocolonic segments (Table 
5). The ileum is scored for the full segment that it is visualized, excluding the 
ileocecal valve and the ileocecal anastomosis. The right colon includes the 
ileocecal valve, the cecum, and the ascending colon up to the hepatic flexure. 
The transverse colon includes the bowel segment from the hepatic flexure to 
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the splenic flexure, and the left colon the descending and sigmoid colon. The 
rectum is defined as the bowel distal to the rectosigmoid junction. The score 
ranges from 0 to 60, with a higher score indicating more severe 
inflammation. The most often used cut-off for remission is 0-2, mild 
inflammation 3-6, moderate inflammation 7-15, and severe inflammation ≥ 
16 (Moskovitz et al. 2007, Sipponen et al. 2008a). Thus, remission as also 
been defined as SES-CD 0-3 (Schoepfer et al. 2010). Both CDEIS and SES-
CD seem to overestimate colonic disease and underestimate ileal disease as 
well as severe but short segmental colonic disease (Sipponen et al. 2008a). 
 
For postsurgical assessment of disease activity, the Rutgeerts score is 
considered the gold standard (Sostegni et al. 2003). The Lemann score, also 
known as the Crohn’s disease digestive damage score (Pariente et al. 2012) is 
a newly developed score that aims to identify CD patients at risk for rapid 
damage progression who would most likely benefit from early induction of 
immunosuppressive or anti-TNF therapy. This score is time-consuming and 
is therefore suitable mainly for clinical studies. New endoscopic techniques, 
such as high-definition endoscopy, magnification endoscopy, filter 
endoscopy, and chromoendoscopy, enable the endoscopist to obtain real-
time in vivo histology views during endoscopy for the generation of optical 
biopsies. Recent studies have used endomicroscopy for in vivo assessment of 
endoscopic activity in IBD. Neumann and coworkers (2012) developed the 
first endomicroscopic activity index to determine the severity of 
inflammation in CD, the Crohn’s Disease Endomicroscopic Activity Score 
(CDEAS). Furthermore, the Watson score, based on cell shedding seen in 
endomicroscopy, has been developed to assess local barrier dysfunction in 
vivo for predicting clinical relapses in CD (Kiesslich et al. 2012). However, 
validation of these new scores is lacking. 
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Table 4. Endoscopic disease activity indices used for Crohn’s disease. 
 
Endoscopic       
index 
Reference Variables or remarks  
    
CDEIS 
Crohn’s disease 
endoscopic index of 
severity 
 
Mary et al. 1989  deep ulcers, superficial ulcerations, surface 
affected by disease (cm), surface affected by 
ulcerations (cm) 
 
SES-CD 
Simple endoscopic 
score for Crohn’s 
disease 
 
Dapero et al. 2004 size of ulcers, ulcerated surface, affected surface, 
presence of narrowing 
 
 
Rutgeerts Score 
 
Rutgeerts et al. 1990 i0: no lesions in the distal ileum 
i1: ≤5 aphthous lesions 
i2: ≥5 aphthous lesions with normal mucosa 
between the lesions, or skip areas of  larger 
lesions or lesions restricted to ileocolonic 
anastomosis 
i3: aphthous ileitis with diffusely inflamed 
mucosa 
i4: diffuse inflammation with large ulcers,  
nodules, or narrowing 
 
 
CDEAS 
Crohn’s disease 
endomicroscopic 
activity score 
 
Neumann et al. 2012 Analysis of mucosa by using fluorescein-aided 
confocal laser endomicroscopy in IBD. 
 Not validated. 
 
Watson Score Kiesslich et al. 2012 Assess local barrier dysfunction in CD in vivo. 
May be used to predict clinical relapse.  
Not validated. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 30 
 
Table 5. Simple endoscopic score for Crohn’s disease (SES-CD). 
 Score 
Variable 0 1 2 3 
Size of 
ulcers 
none 
aphthous ulcers 
(<0.5 cm) 
large ulcers 
(0.5–2.0 cm) 
very large ulcers 
(>2.0 cm) 
Ulcerated 
surface 
none <10% 10–30% >30% 
Affected 
surface 
unaffected <50% 50–75% >75% 
Presence of 
narrowing 
none 
single,  
can be passed 
multiple, 
    can  be passed 
cannot be           
passed 
Daperno M, D’Haens G, Van Assche G, Baert F, Bulois P, Maunour V, Sostegni R, Rocca R, Pera A, Gevers A, 
Mary JY, Colombel JF, Rutgeerts P. Development and validation of a new, simplified endoscopic activity score for Crohn’s 
disease: the SES-CD. Gastrointest Endosc 2004;60:505-512. Reprint with permission from Elsivier. 
 
 
 
6.2.2 Endoscopic scoring in Ulcerative Colitis 
 
There are many scoring systems developed for assessment the endoscopic 
activity in UC (Table 6). The Mayo endoscopy subscore (Schroeder et al. 
1987) has been most commonly used, providing endoscopic subscore from 0 
to 3 and definding mucosal healing as a score of ≤1 (normal mucosa or loss of 
vascular pattern, but no mucosal friability). Recently, the Ulcerative Colitis 
Endoscopic Index of Severity (UCEIS) was developed as the first validated 
index of endoscopic severity. The final UCEIS score includes three 
components (vascular pattern, bleeding, erosions and ulcers), each with 
precise definitions and three or four levels of severity. The UCEIS score seem 
to give precise overall assessment of endoscopic severity of UC, although the 
threshold for MH has not yet been determinated. 
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Table 6. Endoscopic disease activity indices used for UC. 
 
Endoscopic index Reference Variables or remarks  
    
Mayo Endoscopy 
Subscore 
Schroeder et al. 1987  findings of flexible sigmoideoscopy: 
erythema, vascular pattern, friability, 
erosions, ulcers, spontaneous 
bleeding 
 4-point scale 
 
 
Baron Score Baron et al. 1964 vascular pattern, bleeding  
4-point scale 
 
 
Modified Baron Score 
 
Feagan et al. 2005 vascular pattern, friability, bleeding, 
ulcers  
5-point scale 
 
 
Sutherland Index 
Ulcerative colitis disease 
activity index  
 
Sutherland et al. 1987 friability, bleeding  
4-point scale 
 
Powell-Tuck Index 
(St Mark´s index)  
 
 
 
Rachmilewitz Index 
 
 
 
UCEIS 
Ulcerative Colitis 
Endoscopic Index of 
Severity 
Powell-Tuck et al. 1987 
 
 
 
 
Rachmilewitz et al. 1989 
 
 
 
Travis et al. 2012 
20-point scale with 2 additional 
points for endoscopic findings 
(bleeding) 
Mainly based on clinical parameters 
 
granulation, vulnerability, vascular 
pattern, mucosal damage  
12-point scale 
 
vascular pattern, bleeding, erosions 
and ulcers  
3- to 4-point scale 
 
 
 
 
6.2.3 Endoscopic activity and mucosal healing  
 
Endoscopy with biopsies is the golden standard for assessment of intestinal 
inflammation and its extension. Also follow-up endoscopies may be needed 
when speculating on the uncertainty of disease localization, activity, or even 
diagnosis. With the advent of WCE and especially DBE, more complete 
assessment of the small bowel in CD is possible.  
 
The assessment of MH is relevant in both clinical practice and clinical trials. 
Since the 1960’s, clinical studies on UC have suggested a more favorable 
outcome after corticosteroid therapy in UC patients achieving a clinical and 
endoscopic remission than in those only achieving a clinical remission 
(Wright et al. 1966). Until the late 1990’s, studies on CD have shown no such 
correlation (Modigliani et al. 1990). The clinical relevance of MH in patients 
with IBD was first highlighted when treatment with azathioprine was shown 
to promote MH in CD (D’Haens et al. 1997). It was not until the era of TNFα-
blocking therapy that MH has been widely recognized, and recent studies and 
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reviews have suggested that MH should be a therapeutic target in IBD 
(Froslie et al. 2007, Neurath and Travis 2012). Thus, no validated definition 
exists of what constitutes MH in IBD (Sandborn et al. 2002, D’Haens et al. 
2007).  The International Organization for the Study of Inflammatory Bowel 
Disease (IOIBD) proposed a definition of MH in UC as the absence of 
friability, blood, erosions, and ulcers in all visualized segments of gut mucosa 
(D’Haens et al. 2007). Similarly, for CD, the IOIBD tendered a consensus 
definition of MH that includes the absence of ulcers. However, this definition 
requires future validation (D’Haens et al. 2009). Simply stated, MH should 
imply the absence of ulcerations and erosions. Nevertheless, in CD, MH may 
be difficult to achieve.  
 
6.2.4 TNFα-blocking therapy and mucosal healing 
 
In the last 15 years, the advent of TNFα-blocking agents has offered new 
possibilities in the management of IBD. Data available from numerous 
studies have demonstrated that TNFα-blocking therapy can induce and 
maintain MH in IBD patients. In a study of 30 CD patients treated with a 
single dose of infliximab (IFX), a significant decrease in CDEIS in IFX group 
was seen, while patients in the placebo group experienced no endoscopic 
improvement (D’Haens et al. 1999b). In the ACCENT 1 (A Crohn’s Disease 
Clinical Trial Evaluating Infliximab in a New Long-Term Treatment 
Regimen) study (Hanauer et al. 2002), a randomized controlled trial 
evaluating the efficacy of IFX for the treatment of refractory active CD, an 
endoscopic substudy examining MH was performed in 99/573 randomized. 
Patients with induction therapy comprising three infusions of IFX 5 mg/kg 
achieved MH significantly more often than patients receiving only one 
infusion of IFX at baseline (Rutgeerts et al 2004).  Systematic maintenance 
therapy with IFX 5 mg/kg or 10 mg/kg every 8 weeks induced MH at week 54 
in almost half of patients, and sustained MH in approximately 30% of 
patients. Episodic IFX therapy had a negligible impact on MH.  
 
Similarly, in the SONIC (Study of Biologic and Immunomodulator Naïve 
Patients in Crohn’s Disease) trial (Colombel et al. 2010), induction therapy 
with IFX followed by scheduled maintenance treatment every 8 weeks 
resulted in MH in one-third of patients compared with 16% of patients 
receiving azathioprine alone at week 26 (Colombel et al. 2008). The 
EXTEND (extend the safety and efficacy of adalimumab through endoscopic 
healing) trial (Rutgeerts et al. 2012), a placebo-controlled endoscopy trial 
that evaluated the efficacy of ADA for the treatment of moderate-to-severe 
active ileocolonic CD. This trial was one of the first ones to use MH (absence 
of mucosal ulceration) as a primary endpoint. Induction therapy with ADA 
followed by scheduled maintenance therapy resulted in MH in 27.4% and 
24.2% of patients at weeks 12 and 52, respectively, compared with 13.1% and 
0% of patients receiving only induction treatment with ADA followed by 
placebo. The results of this study suggest that MH may be more difficult to 
achieve for patients with more severe ulcerations at baseline. The MUSIC 
(Endoscopic MUcoSal Improvement in Patients with Active Crohn's Disease 
Treated with CZP) trial (Hebuterne et al. 2013) is an open-label study that 
assessed endoscopic improvement of disease in patients with active CD after 
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treatment with certolizumab pegol (CZP). Induction treatment followed by 
scheduled maintenance therapy resulted in endoscopic response (a decrease 
in CDEIS > 5) in about 50%, endoscopic remission (CDEIS < 5) in 27%, and 
MH (defined as the absence of ulcers) in only 8% of patients at week 54. 
Thus, the findings in this trial suggest that patients achieving MH after 
induction therapy (week 10) can maintain MH through week 54.  
 
Anti-TNFα therapy may also lead to MH in UC patients. The ACT1 (Active 
Ulcerative Colitis Trial 1) and ACT2 (Active Ulcerative Colitis Trial 2) trials 
(Rutgeerts et al 2005) investigated the role of IFX in refractory, moderate-to-
severe active UC. MH was defined as a Mayo subscore ≤ 1 and was a 
secondary endpoint. Induction therapy with IFX resulted in MH in 
approximately 60% of patients at week 8. Scheduled maintenance therapy 
with IFX resulted in MH at week 30 in approximately 50% of patients. Data 
available only from the ACT1 trial showed MH in 46% of patients. ULTRA 1 
and ULTRA 2 (Ulcerative colitis long-term remission and maintenance with 
adalimumab) trials, investigated the efficacy of adalimumab (ADA) in 
patients with moderate-to-severe active, refractory ulcerative colitis 
(Reinisch et al. 2011, Sandborn et al. 2012). As in ACT 1 and ACT 2 trials, 
MH was defined as a Mayo subscore ≤ 1 and set as a secondary endpoint. 
These studies demonstrated that induction treatment with resulted in MH in 
one-third of patients at week 8 regardless of whether or not they were 
previously treated IFX. The MH rate at week 52 was 25%. Most recently, 
studies (PURSUIT trials; Program of Ulcerative Colitis Research Studies 
Utilizing an Investigational Treatment) on the efficacy of induction and 
maintenance therapy with subcutaneous GLM in TNFα antagonist-naïve 
patients with moderate-to-severe UC have been published. The primary 
endpoint in the maintenance study was a continuous clinical response among 
GLM induction responders. As in previous studies, MH was a secondary 
endpoint and defined as a Mayo subscore ≤ 1. Approximately 40% of patients 
showed MH at both weeks 30 and 54 (Sandborn et al. 2014a and 2014b).  
 
Differences in achieving MH in CD and UC can be explained by the fact that 
CD is a transmural disease, and therefore, the mucosa is more likely to heal 
in UC. Importantly, the optimal time for assessment of MH remain to some 
extent unresolved (Neurath and Travis 2012).  
 
6.2.5 Clinical impact of mucosal healing 
 
Schnitzler and coworkers (2009) showed in a large cohort study that in 
patients with scheduled IFX therapy MH was associated with fewer 
complications and better long-term outcome. Also patients achieving MH on 
maintenance therapy with IFX have had fewer hospitalizations and surgery 
and have attained a better quality of life (Lichtenstein et al 2002 and 2004). 
MH has also been demonstrated to lead to significantly higher steroid-free 
remission rates in patients with early-stage CD for as long as 4 years after 
start of therapy (Baert et al 2010). A prospective study by the Norwegian 
IBSEN (Inflammatory Bowel South-Eastern Norway) group evaluated the 
course of UC in a population-based inception cohort and identified 
prognostic risk factors. They showed that patients who presented with MH 
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within one year of diagnosis had a significantly lower risk of colectomy 
(Solberg et al. 2009). The CHARM (Crohn’s disease trial of the fully Human 
antibody Adalimumab for Remission Maintenance) study, on the other hand, 
showed fewer hospitalizations and surgery in patients treated with ADA 
versus placebo (Colombel et al. 2007). The relative risk reduction was 57% at 
one year. However, this study lacks endoscopic data. In recent years, it has 
become more obvious that clinical remission alone is not an adequate 
treatment goal in IBD. A growing amount of evidence suggests that MH may 
lead to a better long-term outcome and should therefore be set as a 
comparative treatment goal.    
 
6.2.6 Deep remission  
 
A new therapeutic target in the scientific field is the concept of deep 
remission (DR). The definition of DR is still evolving. However, in CD, DR 
has been applied to patients on immunomodulators or TNFα-blocking 
therapy or both who have no clinical symptoms and no objective signs of 
inflammation (defined as Crohn’s disease activity index [CDAI < 150] and 
endoscopic remission) (Rutgeerts et al 2012). In UC and IBDU, the definition 
of DR has not yet been well-defined.  
 
6.3 Histological activity 
 
Data on the prognostic relevance of histological healing are limited. 
However, several clinical studies indicate that effective medical therapy may 
contribute to MH (D’Haens et al. 1997, 1999a, 1999b, Geboes et al. 2005). 
However, whether histological healing can be achieved in CD with current 
medications and whether histological healing has any impact on the disease 
course remain unknown (Peyrin-Biroulet et al. 2011). On the other hand, 
histological healing seems to be relevant in UC, as microscopic inflammation 
without endoscopic lesions predicts relapse in patients who are in clinical 
and endoscopic remission (Bessissow et al. 2012). Moreover, persistence of 
microscopic inflammation has been stated to be an independent risk factor 
for the development of colorectal cancer in long-standing UC (Gupta et al. 
2007). In a recent study, Lemmens and coworkers (2013) showed a nice 
correlation between the histological and endoscopic activity scores in UC, but 
pointed out also that important misclassifications exist for mild disease. 
Microscopy may detect more severe disease than endoscopically suspected. 
They also suggested that histological scoring should be used in addition to 
endoscopy when scoring disease activity for clinical trials (Lemmens et al. 
2013). Fore these reasons, histological remission should be considered as the 
ultimate therapeutic goal in UC. Histologically, MH in UC is characterized by 
some features related to architectural damage and recovery, such as 
architectural crypt distortion (atrophy and branching), as well as epithelial 
regeneration, disappearance of basal plasmacytosis, and increased 
transmucosal cellularity. However, active inflammation is not usually 
present. Histological findings predicting relapse in patients with quiescent 
UC are basal plasmacytosis, increased transmucosal cellularity, high 
numbers of neutrophils and eosinophils, crypt abscesses, mucin depletion, 
and damage of the surface epithelium (Magro et al. 2013). No general 
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agreement exists among experts as to the value of microscopy in assessing 
CD activity, and therefore, histological remission cannot be a recommended 
endpoint in clinical trials (Sandborn et al. 2002). Several scoring systems for 
histological findings are available. The scoring systems most often used in 
clinical trials are shown in Tables 7 and 8 (D’Haens et al. 1998, 2007). 
 
 
 
Table 7. Histological findings in Crohn’s disease (D’Haens et al. 1998). 
 Score 
Variable 0 1 2 3 
 
Epithelial damage 
 
Normal 
 
Focal 
pathology 
 
Extensive 
pathology 
 
 
Architectural changes Normal Moderately 
disturbed 
(<50%) 
 
Severely 
disturbed 
(<50%)  
Infiltration of 
mononuclear cells in 
lamina propria 
 
Normal Moderate 
increase 
Severe 
increase 
 
Polymorphonuclear 
cells in lamina propria 
 
Normal Moderate 
increase 
Severe 
increase  
Polymorphonuclear 
cells in epithelium 
Normal In surface 
epithelium 
Cryptitis Crypt 
abscess 
Presence of erosion 
and/or ulcers 
No Yes 
 
 
 
Presence of granuloma No Yes   
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Table 8. Histological findings in ulcerative colitis (D’Haens et al. 2007).  
 Score  
Variable 0 1 2 3 4 
 
Structural 
changes 
 
Normal 
 
Mild 
abnormality 
 
 
Mild or 
moderate 
diffuse  or 
multifocal 
abnormality 
 
 
Severe diffuse  
or multifocal 
abnormality 
 
Chronic 
inflammatory 
infiltrate 
 
Normal Mild  
increase 
Moderate 
increase 
Marked 
increase 
 
Infiltration of 
neutrophils  in 
lamina propria 
 
Normal Moderate 
increase 
Severe 
increase 
Marked 
increase 
 
Neutrophils in 
epithelium 
 
None < 5% crypts 
involved 
 
< 50% 
crypts 
involved 
 
> 50% crypts 
involved 
 
Presence of 
crypt 
destruction 
None Probable – 
local excess 
of 
neutrophils 
in part of 
crypt 
 
Probable – 
marked 
attenuation 
Unequivocal 
crypt 
destruction 
 
Presence of 
erosion or 
ulceration 
None Recovering 
epithelium 
Probable 
erosion 
Unequivocal 
erosion 
Ulcer or 
granulaton 
tissue 
 
 
6.4 Blood tests 
 
Anemia, leukocytosis, and thrombocytosis are common in the blood count of 
IBD patients with active disease; however, these findings are usually 
multifactorial. Anemia may develop due to an iron deficiency caused by 
hemorrhage or inflammation, leukocytosis may indicate extensive active 
inflammation or corticosteroid treatment, and thrombocytosis is usually a 
nonspecific response to inflammation, but may also occur during 
hemorrhage. ESR, which indirectly measures the acute-phase plasma protein 
concentration, is elevated during active inflammation as well as in any 
condition that elevates fibrinogen. In UC, the correlation between ESR and 
disease activity is good. However, ESR may be normal in proctitis and 
proctosigmoiditis (Sachar et al. 1986). In CD, the ESR appears to be a less 
accurate measure of disease activity. It appears to increase with increasing 
disease activity, but it correlates more with colonic disease and does not 
reflect the disease activity of the small bowel (Sachar et al. 1990, Desai et al. 
2007). CRP, an acute-phase protein produced by the liver becomes elevated 
with tissue damage caused by inflammation, infection, or injury. The half-life 
of CRP is short; it rises rapidly and falls quickly (Desai et al. 2007). In CD, 
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CRP correlates with disease activity (Vermeire et al. 2004). For UC, the same 
trend is observed, although CRP is lower overall than in CD. More 
importantly, a high CRP value helps to identify UC patients at risk for 
colectomy (Travis et al. 1996). Low serum protein or albumin correlates 
inversely with clinical and endoscopic activity and is indicative for severe 
protein loss or malabsorption (Vermeire et al. 2006, Nikolaus and Schreiber 
2007).  
 
6.5 Cytokines 
Tumor necrosis factor alpha (TNFα) is produced by activated macrophages 
and monocytes. In patients with active IBD, the serum concentration of 
TNFα is often temporarily increased, but not consistently elevated.  
Therefore, the value of serum concentration of TNFα as a surrogate marker 
of IBD activity is limited (Murch et al. 1991, Desai et al. 2007).  The same 
conclusion applies to the measurement of TNFα concentration in stool 
(Braegger et al. 1992). IL-6, a cytokine produced by T-cells and macrophages, 
possesses both anti-inflammatory and pro-inflammatory effects. Elevated 
serum IL-6 concentrations are found in active CD, occasionally in UC 
(Mahida et al. 1992), and the level correlates closely with endoscopic 
findings, being higher in patients with inflammatory CD than with 
stricturating disease (Reinisch et al. 1999). Several other cytokines and 
cytocine receptors, such as IL-1RA, IL-1β, IL-2, IL-2Rα, TNF-RI, TNF-RII, 
IL-1RI, IL-1RII, IL-6, IL-6R, IL-8, IL-10, IL-15, IL-23, and IL-27, have been 
found to be elevated in IBD patients with active disease and may correlate 
with endoscopic and disease activity (Desai et al. 2007).  
6.6 Stool tests 
 
Active IBD inflammation produces activated leukocytes, mainly 
polymorphonuclear neutrophiles, which infiltrate into the intestinal mucosa 
and can be detected in stool because of leukocyte shedding in the intestinal 
mucosa (Tibble et al. 2000a). Potential fecal biomarkers include fecal 
excretion of leukocytes, leukocyte products, and serum proteins (Desai et al 
2007). Several S100-family proteins have been evaluated for their correlation 
with intestinal inflammation, fecal calprotectin being the most extensively 
studied. For detection of IBD inflammation, other useful neutrophil-derived 
biomarkers are lactoferrin (FL), S100A12 (calgranulin C), and 
polymorphonuclear neutrophil elastase (PMN-e).  
 
6.6.1 Fecal calprotectin 
 
Calprotectin is a calcium and zinc binding protein (also known as 
S100A8/S100A9) accounting for 60% of the cytosolic protein content of 
neutrophils (Dale et al. 1985). It is also expressed in activated macrophages 
and monocytes (Johne et al. 1997). Accumulation of neutrophils at the site of 
inflammation in the GI tract results in a release of calprotectin into feces. In 
the presence of calcium, calprotectin is stable and very resistant to bacterial 
degradation, and at room temperature it is stable in stool for up to 7 days 
(Røseth et al. 1992). Fecal calprotectin (FC) excretion has been shown to 
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correlate well with 111Indium test results in CD (Røseth et al. 1992, 1999, 
Tibble et al. 2000a), with histological and endoscopic assessment of disease 
activity in both CD and UC (Røseth et al. 1997, 2004 Sipponen et al. 2008a, 
2008b, 2010a, 2010b, Schoepfer et al. 2010), and also with both disease 
extent and severity in UC (D’Haens et al. 2012). As FC can differentiate 
between active and inactive IBD, it can also differentiate between IBD and 
irritable bowel syndrome (IBS) (Tibble et al. 2002, Schoepfer et al. 2008). 
Gisbert and coworkers (2009a) reported a sensitivity of 83% and a specificity 
of 84% for FC in distinguishing between organic and nonorganic disease. 
Furthermore, FC is known to be specific for inflammation, but is not disease-
specific. It may increase also in other GI inflammatory conditions where 
neutrophils are present such as colorectal carcinoma, diverticulosis, GI 
infections, NSAID enteropathy, microscopic colitis, or even untreated celiac 
disease (Røseth et al. 1993, Tibble et al. 1999, Limburg et al. 2000, Berni 
Canani et al. 2004, Sipponen 2013). For the diagnosis of IBD, FC seems to be 
superior to other serological markers, including CRP, ESR, ANCA, and ASCA 
(Tibble et al. 200oa, 2001, Schoepfer et al. 2007, 2008, Langhorst et al. 
2008). The optimal cut-off value for distinguishing between inactive and 
active IBD remains somewhat unsettled. According to the manufacturer, an 
FC level < 50 µg/g is normal. However, in clinical practice a cut-off value < 
100 µg/g is frequently used for FC to separate inactive and active disease 
(von Roon et al. 2007, Sipponen et al. 2008b), and several other cut-off 
levels have been described in clinical trials (Kornikoff et al. 2006). In active 
inflammation of the gut, FC may rise to tens of thousands of 
micrograms/gram; however, considerable intraindividual variation in FC 
concentration exists (Moum et al. 2010), and even patients without 
inflammation or neoplasm show day-to-day variation in FC release (Huseby 
et al. 2011). Interestingly, FC has a significant positive relationship with 
increasing age, physical inactivity, and obesity and an inverse relationship 
with vegetable consumption and fiber intake (Poullis et al. 2004). Moreover, 
studies of FC in assessing intestinal inflammation are scarce. A UK study 
demonstrated that FC may have a role in assessing small bowel CD, often 
beyond the reach of conventional colonoscopy (Dolwani et al. 2004). A FC 
level > 60 μg/g was shown to predict abnormal barium follow-through 
results, and the negative predictive value of a single FC level < 60 μg/g was 
100%. Somewhat contrary to this, Sipponen and coworkers (2012) found that 
FC had a low utility for predicting the presence of small bowel CD on WCE, 
with a sensitivity of 59% and a specificity of 71% using a cut-off of 50 μg/g.  
 
FC can be quantified from feces by several different enzyme-linked 
immunosorbent assays (ELISAs). In 1992, Roseth and coworkers developed a 
method for extraction of calprotectin from feces and quantification by an 
enzyme-linked immunoassay. The method was improved in 2000, when its 
units were changed from mg/l to µg/g (Tibble et al. 2000a). Recently, rapid 
semiquantitative and quantitative tests have been developed and validated 
for identifying patients with GI inflammation. These tests have been shown 
to detect endoscopic activity and postoperative recurrence as accurately as 
the ELISA tests (Lobaton et al. 2013). The use of these rapid tests in clinical 
practice has been limited, and ELISA test is the most widely used for 
measuring FC concentration. FC allows a noninvasive monitoring of disease 
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activity. However, the ELISA test is time-consuming and requires a well-
trained laboratory personnel, and collection of multiple samples to be cost-
effective. 
 
The clinical course of these chronic, remitting, and relapsing conditions is 
often unpredictable, and the assessment of the severity of IBD and the 
monitoring of disease activity are important issues, in both CD and UC. 
Growing evidence suggests that MH reflects controlled IBD activity with a 
more favorable course (Arnott et al. 2002, Rutgeerts et al. 2007, Van Assche 
et al. 2010b). Low FC level is considered a valuable surrogate marker for 
MH, with high levels indicating a risk of relapse. A growing number of 
studies have demonstrated the ability of a single FC concentration to predict 
clinical relapse in IBD patients with clinically quiescent disease. A list of 
these studies is presented in Table 9. According to these studies, it seems 
that especially in colonic CD and UC, a single elevated FC concentration in 
clinically inactive IBD patients predicts a clinical relapse within one year. 
More recently, a meta-analysis of six prospective studies showed a pooled 
sensitivity of 78% (95% CI 72–83%) and a specificity of 73% (95% CI 68–
77%) for FC in predicting IBD relapse (Mao et al. 2012). The study of 
infliximab discontinuation in Crohn’s disease patients in stable remission on 
combined therapy with immunosuppressors (STORI trial), the largest study 
exploring the duration of remission in CD after discontinuation of TNFα-
blocking therapy, showed that FC concentration >300 μg/g at inclusion was 
an independent factor associated with disease relapse and concluded that an 
elevated FC concentration predicts the risk of IBD relapse (Louis et al. 2012).  
 
 
 
Table 9. Studies investigating the use of FC to predict relapse in IBD patients. 
Reference Number of patients 
and diagnosis 
FC cut-off 
(μg/g) 
 
Tibble et al. 2000b 
Tibble et al. 2000b 
Costa et al. 2005 
Costa et al. 2005 
D’Inca et al. 2008 
D’Inca et al. 2008 
Walkiewicz et al. 2008 
Diamanti et al. 2008 
Gisbert et al. 2009 
Gisbert et al. 2009 
Kallel et al. 2010 
Sipponen et al. 2010b 
37; UC 
43; CD 
41;UC 
38; CD 
97; UC 
65; CD 
32; CD 
73; UC/CD 
162; UC 
162; CD 
53; CD 
72; UC/CD  
> 50 
> 50 
> 150 
> 150 
> 130 
> 130 
> 130 
> 275 
> 150 
> 150 
> 150 
> 340 
 
 
 
 
 
 
 
 
 
 
 
 
 
> 340 
 
FC = fecal calprotectin; UC = ulcerative colitis; CD =Crohn’s disease 
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6.6.2 Lactoferrin and S100A12  
 
Lactoferrin (FL) and S100A12 are the other two potential fecal surrogate 
markers for monitoring IBD patients in clinical practice. FL is an iron-
binding glycoprotein secreted by most mucosal membranes that interact 
directly with external pathogens. FL is a major component of the secondary 
granules of polymorphonuclear neutrophils, which are a primary component 
of the acute inflammatory response (Kayazawa et al. 2002), and can be 
detected in mammalian milk, saliva, semen, tears, bile, and mucosal 
secretions. Like calprotectin, FL is a nonspecific marker of intestinal 
inflammation and can be detected in several conditions besides IBD, such as 
infective diarrhea, colon neoplasia, and acute radiation-induced proctitis 
(Uchida et al. 1994, Dai et al. 2007, Hille et al. 2008). Many previous studies 
have indicated the potential usefulness of measuring FL in patients with IBD 
(Fine et al. 1998, Tibble and Bjarnason 2001, Kane et al. 2003). During 
inflammation FL levels quickly increase (Desai et al. 2007), and correlations 
between FL and endoscopic and/or histological activity in IBD patients have 
been detected (Langhorst et al. 2008, Sipponen et al. 2008a, 2008b). FL has 
also been shown to predict relapse in IBD patients, as Gisbert and coworkers 
(2009a) reported a sensitivity of 62% and a specificity of 65% in predicting 
relapse in clinical remission. 
 
Neutrophil-derived protein S100A12, also known as calgranulin C, has been 
suggested as a fecal marker of intestinal inflammation. It is a member of the 
damage-associated molecular pattern proteins and is released from 
neutrophils or monocytes under conditions of cell stress. S100A12 is 
remarkably resistant to degradation by fecal bacteria, and fecal specimens 
show stability for at least 7 days at room temperature (de Jong et al. 2006).  
A growing amount of data indicates S100A12 to be a suitable marker of IBD, 
and several studies have demonstrated a correlation between mucosal 
inflammation and S100A12 levels in blood (Leach et al. 2007, Manolakis et 
al. 2010) and feces (de Jong et al. 2006, Kaiser et al. 2007) of patients with 
IBD. Fecal S100A12 is a promising marker of intestinal inflammation, with 
specificity superior to FC in predicting IBD relapse. Higher baseline levels of 
fecal S100A12 are significantly associated with disease relapse during the 
course of the disease, and fecal S100A12 levels are already increased up to 6 
months before clinical relapse in both CD and UC (Däbritz et al. 2013). 
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7 Treatments 
 
Treatment goals in IBD include induction and maintenance of remission, 
mucosal healing, avoidance of hospitalization and surgery, minimizing the 
risk of cancer, and optimizing the quality of life. When making decisions on 
medical therapy, severity of the disease (mild, moderate, severe), localization 
(CD: ileal, ileocolonic, colonic, or other; UC: extensive, left-sided, or 
proctitis), and behaviour in CD (inflammatory, stricturing, or fistulating) 
should be taken into consideration. Factors that contribute to the individual 
management of IBD patients include extraintestinal manifestation of IBD 
and comorbidities, patient preferences and benefits, intolerance to 
medications, and also such life situations as schooling, work, and family life 
that may particularly influence the timing and choice of some treatments. In 
some CD patients with mild disease, no medication can be an option. As 
smoking cessation in CD is associated with a more benign disease course and 
better treatment outcomes, smoking cessation advice should be offered to all 
patients (Cosnes et al. 2001). No curative drug is available.  
 
7.1 Medical therapy 
 
7.1.1 Conventional therapy 
 
Corticosteroids have been used in active IBD since 1955, when Truelove and 
Witt published their study on the efficacy of corticosteroid treatment in 
active UC. Most IBD patients respond to the first-line corticosteroid therapy, 
but more than half will develop a steroid-dependent or steroid-resistant 
disease already at one year (Munkholm et al. 1994). MH can be achieved only 
in about one-third of IBD patients. In mildly active ileocecal CD, enteric-
coated budesonide is a treatment option. It has fewer unwanted systemic 
side-effects than conventional corticosteroid therapy, because of its rapid 
hepatic conversion to metabolites. Even so, severely active or extensive 
ileocecal or ileal CD should be treated with systemic corticosteroids (Dignass 
et al. 2010). Corticosteroids play no role in maintaining remission. 
 
5-aminosalicylic acid (5-ASA) drugs are the mainstay of therapy for mild to 
moderate UC. The standard first-line induction therapy for distal UC involves 
topical 5-ASA drugs, which have a more rapid effect than oral therapy. A 
combination of oral and topical 5-ASA appears to provide a further benefit. 
Sulfasalazine is as effective as mesalazine, but has more side-effects and 
adverse events than mesalazine (Dignass et al. 2012a). In UC, oral 5-ASA 
treatment can induce and maintain remission in minority of patients, while 
in CD the effect of 5-ASA on induction or maintenance of remission is limited 
(Hanauer and Strömberg 2004).  
 
Immunomodulative therapy for IBD consists of thiopurines (azathioprine 
and 6-mercaptopurine) and metotrexate. Thiopurines have been shown to be 
effective and superior to 5-ASA in inducing and maintaining remission in 
steroid-dependent or steroid-refractory UC (Ardizzone et al. 2006) and can 
successfully prevent relapse in patients resistent to 5-ASA therapy. 
Immunomodulative therapy is also recommended for postoperative 
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prophylaxis of complex CD and for extensive small bowel disease (Dignass et 
al. 2010). In active CD, thiopurines induce and maintain remission and lead 
to MH (D’Haens et al. 1997, 1999a, Prefontaine et al. 2009, 2010). In 
patients requiring rapid induction of remission, thiopurines are unsuitable 
because of their slow onset of action (Dignass et al. 2010, 2012a). 
Methotrexate is more effective than placebo in inducing and maintaining 
clinical and endoscopic remission in active CD during intramuscular therapy 
(Feagan et al. 2000).  
 
Due to the role of the microbiome in IBD pathogenesis, interest in the use of 
probiotics in IBD has grown. Promising results have emerged for E. coli 
Nissle in inactive UC to induce clinical remission. Also the probiotic mixture 
VSL#3 has been shown to be more effective than placebo in inducing clinical 
response in active UC (Dignass et al. 2012a). No evidence to support the use 
of probiotics in CD is available (Dignass et al. 2010). 
 
Antibiotics, such as ciprofloxacin and metronidazole, are appropriate in 
treating infectious complications, perianal disease, and bacterial overgrowth 
(Dignass et al. 2010, 2012a). Table 10 shows the MH rates in different 
treatment groups.  
 
 
 
 Table 10. Conventional medical therapy and mucosal healing rates. 
 
Medical therapy  Mucosal healing rates References 
 Crohn’s disease Ulcerative colitis  
    
Corticosteroids: 
   predniso(lo)ne 
   budesonide 
 
29% at 7 weeks 
24% at one year 
 
 
 
Modigliani et al. 1990 
Mantzaris et al. 2009 
Mesalazine  80% at week 6 
32-78% at week 8 
Lichtenstein et al. 2011 
Kamm et al. 2007  
Sandborn et al. 2007a 
Lichtenstein et al. 2007 
Kruis et al. 2009 
Thiopurines: 
   azathioprine  
 
16% at week 26 
53-70% at 9 months 
83% at one year 
 
 
37-63%  
at 4 months 
53-69%  
at 6 months 
 
 
Panaccione et al. 2011  
Ardizzone et al. 2006  
Lopez-Palacion et al. 2011 
Colombel et al. 2010 
D’Haens et al. 1999a  
Mantzaris et al. 2009 
 
Methotrexate 11-36% at week 12  Manosa et al. 2010  
Laharie et al. 2011  
McDonald et al. 2012 
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7.1.2 TNFα-blocking agents 
 
The pro-inflammatory cytokine TNFα plays an important role in the 
pathogenesis of IBD. Anti-TNFs interrupt the inflammatory process by 
neutralizing this cytokine by several mechanisms. TNFα-blocking agents are 
biological drugs, thus produced by biological processes.  
 
7.1.2.1 Indications for TNFα -blocking agents in IBD  
 
Anti-TNF antibodies have been found to be an effective treatment for 
moderate to severe CD and UC.  However, the optimal timing of anti-TNFα 
therapy may be difficult to determine. A therapy started too late will be 
unable to impact the surgical rate. CD patients with extensive or perianal 
disease, abdominal or complex perianal fistulizing lesions, or multiple deep 
ulcers and UC patients with severe extensive colitis with no response to 
steroids, may benefit the most from the early onset of anti-TNF therapy. 
 
IFX is an intravenously administered murine-divided chimeric IgG1 anti-
TNF monoclonal antibody with potent anti-inflammatory effects, possibly 
dependent on apoptosis of inflammatory cells. Induction therapy with IFX at 
a dose of 5 mg/kg or 10 mg/kg at 0, 2, and 6 weeks followed by maintenance 
therapy every 8 weeks can be considered in outpatients with steroid-
dependent or -refractory disease and should be used in patients failing 
azathioprine or 6-mercaptopurine monotherapy in both CD and UC. In 
severe or fulminant UC, IFX is superior to ADA (Dignass et al. 2012a). 
Patients with active fistulizing CD despite treatment with antibiotics and AZA 
or 6-MP can be treated with IFX (at 0, 2, and 6 weeks for induction, and then 
every 8 weeks for maintenance) as monotherapy or combined with other 
immunomodulating agents (Present et al. 1999, Sands et al. 2004, Colombel 
et al. 2010). 
 
ADA is a subcutaneously (SC) administered, recombinant, fully human, 
immunoglobulin G1 monoclonal antibody that binds with high affinity and 
specificity to human TNF, but not to lymphotoxin, and modulates biologic 
responses induced or regulated by TNF (Sandborn et al. 2012). ADA is given 
subcutaneously 160 mg at week 0 and 80 mg at week 2, and then 40 mg 
every other week beginning at week 4 or if necessary weekly for maintenance 
in both CD and UC (Hanauer et al. 2006, Colombel et al. 2007, Sandborn et 
al. 2007b, 2012a). ADA has also been demonstrated to be effective in 
fistulizing CD, and in patients who have developed antibodies against IFX 
(Rutgeerst et al. 2012).  
 
GLM is a subcutaneously (SC) administered, fully human, anti-TNF 
antibody, approved for the treatment of UC in 2013. GLM seem to have 
similar efficacy in UC as ADA, however, its advantages compared with IFX 
and ADA are its low immunogenicity, weight-based, and once-monthly 
administration (Sandborn et al. 2014a, 2014b). No trials on the efficacy of 
GLM in CD exist.  
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Biosimilars of antibodies to TNFα are becoming important in the treatment 
of IBD. Experience with simple peptide biosimilars, such as epoetins and 
growth factors, has generally been positive, with these biosimilars having 
similar efficacy and safety as the original products. So far, only an IFX 
biosimilar is available. However, immunogenicity remains a major concern. 
Future studies will address concerns on biosimilars in IBD, including their 
efficacy, safety, immunogenicity, switching, and interchangeability. 
 
Other immunomodulatory agents, such as cyclosporine, tacrolimus 
mycophenolate mofetil, thalidomide, and thioguanine, have also been 
advocated in the management of IBD (Dignass et al. 2010, 2012a). These 
treatments will not be discussed in any detail in this review. A strong need 
exists for more effective medication, especially in CD, where surgery is not a 
curative treatment option. CZP is a pegylated, subcutaneously administered 
humanized anti-TNF Fab (fragment antigen binding) -antibody fragment 
with proven clinical efficacy despite the lack of pro-apoptotic effects 
(Schreiber et al. 2005). Earlier studies have shown CZP to have similar 
efficacy as other TNFα-agents especially in anti-TNF-naїve CD patients and 
those failing IFX therapy (Sandborn et al. 2007c, 2010, Schreiber et al. 
2007). Thus, CZP has no indications in Finland. Vedolizumab, a fully 
humanized α4β7 integrin antibody, is more effective than placebo in inducing 
and maintaining remission in both CD and UC (Feagan et al. 2013, Sandborn 
et al. 2013b). After natalizumab, a α4-integrin, resulted in reactivation of 
human papillomavirus, leading to a progressive multifocal 
leukoencephalopathy (PLE), some concerns have been rased. As vedolizumab 
modulates only the gut, not the brain, no cases of PLE have emerged (Soler et 
al. 2009). The priminary data on ustekinumab, IL-12 and IL-23 inhibitors, 
suggest that it might be effective in particular in CD patients failing TNFα-
blocking therapy (Sandborn et al. 2012b). Other IL-12 and IL-23 inhibitors, 
such as apilimod and briakinumab, are still in phase II trials. Tofacitinib, an 
inhibitor of Janus kinases 1, 2, and 3, has shown promise in UC treatment, 
and trials on tofacitinib have advanced to phase III (Sandborn et al. 2012c). 
 
7.1.2.2. Efficacy and safety of TNFα-blocking therapy 
 
Data on efficacy, treatment outcomes, and safety of TNFα-blocking therapy 
in IBD are extensive.  
 
IFX has been demonstrated to be efficacious for the treatment of refractory 
luminal and fistulizing CD in several studies. In the short term, up to 80% of 
patients experience a rapid improvement of their symptoms and up to 50% 
have a complete remission (Present et al. 1999, Hanauer et al. 2002, 
Rutgeerts et al. 2004a). With scheduled maintenance treatment, IFX not 
only maintains disease improvement, but also induces clinical improvement 
in about two-thirds of patients and MH in nearly half of the treated patients 
(Present et al. 1999, Hanauer et al. 2002, Sands et al. 2004, Rutgeerts et al. 
2006). Data from the ACCENT I and II (A Crohn’s Disease Clinical Trial 
Evaluating Infiximab in a New Long-term Treatment Regimen in Patients 
With Fistulizing Crohn’s Disease) studies also show that scheduled treatment 
with IFX decreases the rate of hospitalizations and surgical interventions 
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(Hanauer et al. 2002, Sands et al. 2004). Patients achieving MH on 
maintenance therapy with IFX experience fewer hospitalizations and 
surgeries, have a better quality of life, and also have a better long-term 
outcome (Lichtenstein et al. 2002, 2004, Schnitzler et al. 2009). In UC, data 
on long-term outcome of TNFα-blocking therapy are based mainly on the 
ACT 1 trial. Scheduled maintenance therapy with IFX 5 mg/kg resulted in 
clinical remission in about 35% and MH in about 46% of patients by week 54 
(Rutgeerts et al. 2005). Recently published data (the UC SUCCESS trial; the 
study of efficacy and safety of infliximab and azathioprine therapy alone or in 
combination for ulcerative colitis) revealed that combination treatment with 
IFX and azathioprine in UC patients resulted in higher remission rates than 
IFX or azathioprine monotherapy (Panaccione et al. 2014). In addition, a 
detectable trough in serum IFX predicts clinical remission, endoscopic 
improvement, and a lower risk of colectomy in UC patients (Seow et al. 
2010).  
 
ADA has been effective in inducing clinical response and remission in both 
TNF-naïve and IFX-failure patients (Hanauer et al. 2006, Sandborn et al. 
2007b, 2009). The CHARM I and II studies demonstrated a steroid-free 
clinical remission rate at week 56 for 29% of patients, and also fewer 
hospitalizations and surgery (Colombel et al. 2007, Feagan et al. 2008).  
Unfortunately, these studies lack endoscopic data. The SONIC study showed 
a steroid-free clinical remission rate at week 26 of 44% (Colombel et al 2010). 
However, according to the EXTEND trial, DR, defined as a combination of 
clinical remission (CDAI <150) and complete MH, was achievable in some 
19% of patients by week 52 (Rutgeerts et al. 2012). Importantly, in a recent 
study of patients with moderate to severe ileocolonic CD who received ADA 
induction and maintenance therapy, patients achieving deep remission 
appeared to have better one-year outcomes than those not achieving DR 
(Colombel et al. 2014). In the ULTRA I and II trials, ADA-treated patients 
achieved clinical remission significantly more often at week 8 and week 52 
(Reinisch et al. 2011, Sandborn et al. 2012a). ADA treatment is associated 
with a positive benefit/risk balance in the overall population of patients with 
moderate-to-severe active UC in ULTRA 2; moreover, early response was 
predictive of a positive outcome at one year (Sandborn et al. 2013a). 
 
Based on the outcomes of the PURSUIT-SC induction study, induction 
treatment with GLM was concluded to be effective and safe for patients with 
moderate to severe active UC. Even so, the clinical remission and MH rates at 
week 6 are fairly low. The PURSUIT maintenance study demonstrated 
continuous clinical response (primary endpoint), clinical remission, and MH 
(secondary endpoints) at week 30 and week 54 among GLM induction 
responders significantly more often in patients receiving active treatment 
with 50 mg and 100 mg of GLM versus placebo (Sandborn et al. 2014b). 
Clinical response, clinical remission and MH rates of TNFα-blocking therapy 
are summarized in Tables 11 and 12. 
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 Table 11. Endpoints of induction and maintenance with TNFα-blocking therapy in 
CD. 
 
Study Reference 
Anti-
TNF used 
Clinical  
response rate 
Clinical remission 
rate 
Mucosal healing 
rate 
ACCENT 1 
Hanauer 
et al. 2002 
IFX  
  
At week 30 
39% (5 mg/kg) 
45% (10 mg/kg) 
 
 
 
Endoscopic 
substudy of 
ACCENT I 
Rutgeerts  
et al. 2006 
IFX  
 
 
At week 54 
46% (5 mg/kg) 
53% (10 mg/kg) 
 
EXTEND 
Rutgeerts  
et al. 2012 
ADA  
 
 
 
 
At week 12; 47% 
At week 52; 33%  
At week 12; 27% 
At week 52; 24% 
CLASSIC I 
Hanauer 
et al. 2006 
ADA  
 At week 4  
18% (40/20 mg) 
24% (80/40 mg) 
36% (160/80 mg) 
 
CHARM 
Colombel  
et al. 2007 
ADA  
At week 26 
(40 mg eow/ew)   
89%/82% 
At week 56 
71%/75% 
 
        At week 26 
(40 mg eow/ew) 
40%/47% 
At week 56 
36%/41% 
 
 
CHARM 
(open label 
extension) 
 
Panaccione  
et al. 2010 
ADA  
 At 2 years 
42% (40 mg eow) 
50% (40 mg ew) 
 
 
CHARM 
(open label 
extension) 
 
Loftus 
et al. 2009 
 
ADA 
 
 
 
At 2 years; 67% 
At 3 years; 69% 
 
SONIC 
 
Colombel  
et al. 2010 
ADA  
 
At week 26; 44% 
 
ADA = adalimumab; IFX = infliximab; eow = every other week; ew = every week 
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 Table 12. Endpoints of induction and maintenance with TNFα -blocking therapy in 
UC. 
 
Study Reference 
Anti-
TNF used 
 Clinical response rate 
Clinical 
remission rate 
Mucosal 
healing rate 
ACT I  
Rutgeerts 
et al. 2005 
IFX  
At week 8 
65% (5 mg/kg) 
69% (10 mg/kg) 
At week 30 
47% (5 mg/kg) 
60% (10 mg/kg) 
At week 54 
46% (5 mg/kg) 
44% (10 mg/kg) 
 
 
At week 8 
39% (5 mg/kg) 
32% (10 mg/kg) 
At week 30 
34% (5 mg/kg) 
35% (10 mg/kg) 
At week 54 
35% (5 mg/kg) 
34% (10 mg/kg) 
 
 
At week 8 
62% (5 mg/kg) 
57% (10 mg/kg) 
At week 30 
50% (5 mg/kg) 
49% (10 mg/kg) 
At week 54 
46% (5 mg/kg) 
47% (10 mg/kg) 
 
 
ACT II 
Rutgeerts 
et al. 2005 
IFX  
At week 8 
65% (5 mg/kg) 
69% (10 mg/kg) 
At week 30 
47% (5 mg/kg) 
60% (10 mg/kg) 
 
 
At week 8 
34% (5 mg/kg) 
27% (10 mg/kg) 
At week 30 
26% (5 mg/kg) 
36% (10 mg/kg) 
 
 
At week 8 
60% (5 mg/kg) 
62% (10 mg/kg) 
At week 30 
46% (5 mg/kg) 
57% (10 mg/kg) 
 
 
ULTRA 1 
Reinisch 
et al. 2011 
ADA  
At week 8 
52%  
(80/40 mg) 
55% 
 (160/80 mg) 
At week 8 
10% 
(80/40 mg) 
19%  
(160/80 mg) 
At week 8 
38%  
(80/40 mg) 
47%  
(160/80 mg) 
 
ULTRA 2 
Sandborn 
et al. 2012a 
ADA  
 
At week 52 
30% 
 
 
At week 52  
17% 
 
At week 52  
25% 
PURSUIT 
SC 
Induction 
Sandborn 
et al. 2014a 
GLM  
At week 6 
51% 
 (200/100 mg) 
55%  
(400/200 mg) 
 
 
At week 6 
18%  
(200/100 mg) 
18%  
(400/200 mg) 
 
At week 6 
42%  
(200/100 mg) 
45%  
(400/200 mg) 
 
PURSUIT 
maintenance 
Sandborn 
et al. 2014b 
GLM  
At weeks  
30 and 54 
47% (50 mg) 
50% (100 mg) 
At weeks  
30 and 54 
23% (50 mg) 
28% (100 mg) 
At weeks  
30 and 54 
42% (50 mg) 
42% (100 mg) 
ADA = adalimumab; GLM = golimumab; IFX = infliximab 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 48 
 
Unfortunately, a significant proportion of IBD patients, especially UC 
patients, do not respond to TNFα-induction therapy (primary 
nonresponders) or require dose escalation due to loss of response over time 
(secondary nonresponders). Determination of serum trough levels (TL), anti-
infliximab antibodies (ATI), and anti-adalimumab antibodies (ATA) has been 
proposed as a method to optimize anti-TNF therapy. A detectable trough 
level has been demonstrated to be a strong predictor for remission in both 
CD and UC (Maser et al. 2006, Seow et al. 2010). Development of ATI is 
early in the course of treatment and can cause loss of drug efficacy and 
adverse reactions such as infusion reactions. Episodic treatment with IFX is 
associated with a higher likelihood of developing ATI (30–61%) than 
maintenance treatment (7–10%) or treatment with immunomodulators (10–
43%) (Hanauer et al. 2004, Baert et al. 2003). In some cases, adverse events 
require discontinuation of therapy, and in these cases switching to another 
anti-TNF agent is generally recommended.  
 
Treatment with anti-TNF agents seems to be relatively safe (Blonski and 
Lichtenstein 2007, Hoentjen et al. 2009, Lees et al. 2009, Lichtenstein et al. 
2012, Burmester et al. 2013). The most common side-effects are acute 
infusion reactions (<4–23%) or injection-site reactions (13.3–29.3%) and 
infections (20.8–49.4%). Severe infections are significantly more uncommon 
(3.0–9.9%). Other reported side-effects, such as delayed hypersensitivity 
reactions most typically with arthralgia and muscle ache, serum sickness-like 
reactions, drug-induced lupus, demyelinating complications, other 
autoimmune diseases, and malignancies, are relatively rare. Acute infusion 
reactions are seldom serious and can be treated with prophylactic 
antihistamines or a single dose of hydrocortisone. After a period exceeding 4 
months of no drug treatment, patients are more likely to develop antibodies 
against anti-TNF agents and therefore to suffer from infusion reactions. 
Prophylactic medication should be considered for these patients. Current 
data from clinical trials do not indicate that patients treated with IFX have an 
increased risk of developing lymphoma (Rutgeerts et al. 2004b). However, a 
recent meta-analysis of 6 studies found that patients treated with 
azathioprine or 6-mercaptopurine had a more than 4-fold increase in the risk 
of lymphoma, and therefore the association between IFX and lymphoma is 
remains obscure (Kandiel et al. 2005). Moreover, the TREAT (Crohn’s 
Therapy, Resource, Evaluation, and Assessment Tool) registry demonstrated 
no significant increase for malignancies in patients treated with IFX 
(Lichtenstein et al. 2012). Similar results heve also been reported with other 
anti-TNF agents. Most recently, Osterman and coworkers (2014) 
demonstrated that the incidence of malignancy with ADA monotherapy in 
CD patients is equal to that of the general population. However, an 
aggressive hepatoplenic T-cell lymphoma has been associated with the use of 
anti-TNF agents (Shale et al. 2008). It is still unclear whether the anti-TNF 
agents used, the thiopurine therapy, the concomitant immunosuppressive 
therapy, or the underlying disease, separately or in combination, are risk 
factors for the development of these lymphomas. Despite improved disease 
control with combination therapy, it is conceivable that high levels of 
immunosuppression could increase the risk of complications, including 
death. Moreover, a concomitant immunosuppression appears to be an 
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important risk factor for infections during TNFα-blocking therapy. Serious 
opportunistic infections, such as tuberculosis and histoplasmosis, occur at a 
higher incidence when concomitant immunosuppression is employed. In any 
case, the absolute incidence of opportunistic infections and mortality are low 
(Toruner et al. 2008, Colombel et al. 2004). Side-effects associated with 
TNFα-blocking therapy are summarized in Table 13.  
 
 
Table 13. Most typical side-effects associated with anti-TNF therapy. 
 
Side-effects Example References 
   
Infections Tuberculosis  
Histoplasmosis 
Candidasis 
Aspergillosis 
Pneumonia 
 
Keane et al. 2001 
Hanauer et al. 2002 
Tsiodras et al. 2008 
Toruner et al. 2008  
Sandborn et al. 2004 
Colombel et al. 2004 and 2007 
Burmester et al. 2012 
 
 
Antibody formation 
and autoimmunity 
Antibodies to infliximab 
Antibodies to adalimumab 
Antinuclear antibodies 
Sand et al. 2002  
Baert et al. 2003 
Vermeire et al. 2003  
Rutgeerts et al. 2005  
Sandborn et al. 2007b 
 
Infusion reaction 
/injection-site 
reactions 
Anaphylaxis 
Serum sickness-like disease 
Delayed-type hypersensitivity 
Rash 
 
Cheifetz et al. 2003  
Hanauer et al. 2002 and 2006 
Colombel et al. 2007 
Sandborn et al. 2007b 
 
Demyelization Demyelinating neuropathy 
Guillain-Barre syndrome 
Mohan et al. 2001 
Shin et al.2006 
Malignancies Lymphomas (RA) 
Hepatosplenic T-cell lymphoma 
Non-melanoma skin cancer 
 
Hanauer et al. 2002  
Bongartz et al. 2006 
Shale et al. 2008 
Burmester et al. 2012 
 
Abnormal liver 
function tests 
Hepatitis 
Cholestatic diseases 
 
Menghini et al. 2001 
Moum et al. 2007 
 
Dermatological 
symptoms 
 
Psoriatic dermatitis Fidder et al. 2007 
Other Joint pain and myalgias 
Parethesias, weakness 
Headache, dizziness 
Nausea and vomiting 
Chest pain, dyspnea, and cough 
Sandborn et al. 2004 
Rutgeerts et al. 2005 
Schreiber et al. 2005 
 
RA = Rheumatoid arthritis  
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7.1.2.3 Discontinuation of TNFα-blocking therapy 
 
Despite the favorable effects of TNFα-blocking therapy, the fear of side-
effects, intolerance, or desired pregnancy may necersitate discontinuation of 
TNFα-blocking therapy. Also, quite disappointingly, a recent systematic 
survey and meta-analysis demonstrated no reduction in the need for surgery 
in IBD patients on TNFα-blocking therapy (Ehteshami-Afshar et al. 2011). 
Another important basis for stopping TNFα-blocking therapy is economical. 
Sensitivity analyses have highlighted the fact that cost-effectiveness is to 
some extent influenced by the treatment duration, and that treatments 
beyond 4 years not being cost-effective (Bodger et al. 2009).  
 
Data available on treatment withdrawal are limited. The observational, 
prospective STORI trial of 115 CD patients showed that stopping IFX while 
on combination therapy with immunomodulators leads to clinical recurrence 
in approximately 50% of cases within 1 or 2 years, with a median time to 
relapse of 16.2 months (Louis et al. 2012). The STORI trial identified male 
gender, absence of previous surgical resection, steroid treatment in the 
preciding 6-12 months, CDEIS > 0, hemoglobin ˂ 145 g/L, white blood count 
˃ 6.0x109/L, CRP level ˃ 5.0 mg/L, FC ˃ 300 µg/g, and high drug trough 
level as predictors of relapse after the discontinuation of IFX. In a 
longitudinal cohort study, Waugh and coworkers (2010) enrolled 48 patients 
with CD in full steroid-free clinical remission for at least 6 months who had 
discontinued IFX for reasons other than loss of response and monitored 
these patients for up to 7 years. Up to 50% of these patients relapsed within 
477 days after IFX discontinuance. More importantly, 35% of patients 
remained well and without clinical relapse. No risk factors for relapse were 
indentified in this study. An observational cohort study explored the long-
term clinical benefit of IFX in 614 consecutive patients with CD, 577 having 
an initial response to IFX. During follow-up, approximately one-third had to 
stop the medication because of side-effects, loss of response, or other 
reasons. Altogether 110 patients in clinical remission stopped IFX and 
remission was maintained for a median of 47.3 months (Schnitzler et al. 
2009). In a follow-up study “step up versus step down” (D’Haens et al. 
2008), 49 patients with early-stage CD who underwent ileocolonoscopy after 
2 years of therapy were followed up for an additional 2 years. Of 24 patients 
with complete MH, 17 maintained remission without steroids and of these 17 
patients, 15 maintained remission without IFX and three were in remission 
without even an immunomodulator (Baert et al. 2010). This study indicated 
that a conventional step-up strategy and the presence of mucosal damage 
predict a relapse in years 3 and 4. In an observational Danish single-center 
retrospective study, 53 patients with CD and 28 patients with UC stopped 
IFX while in steroid-free remission, and these patients were monitored for 
up to 10 years. In this cohort, 61% of patients with CD remained in remission 
at one year, the proportion dropping to 50% and 12%, at 2 and 10 years, 
respectively. Of the patients with UC, 75% were still in remission at one year 
and 40% after 4.5 years (Steenholdt et al. 2012). CD patients with longer 
disease duration at the onset of TNFα-blocking therapy relapsed more often, 
but as in UC, no risk factors for relapse could be identified. Rismo and 
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coworkers (2013) presented a study of 37 patients treated with either IFX or 
ADA with complete MH documented by colonoscopy. The median time to 
clinical relapse was 26 weeks, with 7 of 27 evaluated patients (26%) still in 
remission by week 52. Univariate analyses showed differences in mucosal 
cytokine levels (IL-17A and TNFα expression) between patients relapsing and 
those sustaining remission. In an observational prospective cohort, IFX or 
ADA was discontinued in 121 patients in clinical remission after one year of 
therapy. In this study, only one-third of patients agreed to undergo 
colonoscopy, which showed MH in only 35%. During a one year follow-up, 
45% of patients had clinical relapse and restarted biologics (Molnar et al. 
2013). The authors found a dose intensification during the one year course of 
anti-TNF therapy, previous biological therapy, smoking and steroid therapy 
at the time of induction, elevated CRP level at the beginning and end of 
therapy, and male gender to be predictors of a need for restarting biological 
therapy. In a recently published study of 51 UC patients in clinical remission, 
35% needed to be retreated with IFX within one year after treatment 
cessation (Farkas et al. 2013). 
 
Existing guidelines have concluded that due to limited evidence no 
recommendations can be made regarding in whom and when to discontinue 
TNFα-blocking therapy after attaining clinical remission (Dignass et al. 
2010, 2012a, D’Haens et al. 2011). A multidisciplinary European expert panel 
(European Panel on the Appropriateness of Crohn’s Disease Treatment II, 
EPACT-II) considered discontinuation of TNFα-blocking therapy in CD to be 
appropriate after 4 years, but also after 2 years of therapy if the patient was 
in DR. Nonetheless, in clinical practice, the decision on whether to continue 
or discontinue treatment in IBD patients in clinical or endoscopic remission 
is still mostly based on assessment of the patient’s individual risks and 
benefits. 
 
7.1.2.4 Reinitation of TNFα -blocking therapy 
 
The existing data on re-initation of TNFα-blocking therapy confirm the 
response to be effective and well tolerated.  In the STORI trial, patients were 
retreated after a mean drug holiday of 6.6 months (Louise et al. 2012). After 
only two infusions of IFX, 88% of patients were in clinical remission and 
98% had a clinical response. As there is a risk of immunization resulting in 
hypersensitivity reactions when restarting medication after a drug-free 
interval, it is important to note that none of the patients were positive for ATI 
before retreatment. Also Steenholdt and coworkers (2012) report an excellent 
outcome after retreatment; 96% CD patients and 71% of UC patients 
achieved complete clinical remission. Reassuringly, Molnár and coworkers 
(2013) reported that retreatment with biologics was effective in 55% of CD 
patients and 94% of UC patients after clinical relapse resulting from 
discontinuation of TNFα-blocking therapy. 
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7.2 Surgical therapy 
 
As a general rule, surgery is the appropriate choice of treatment in UC when 
medical treatment options have failed, particularly in severe acute colitis or 
chronically active steroid-dependent colitis, or when the risk of malignancy is 
high, i.e. in dysplasia or cancer of the colon (Mowat et al. 2011). Despite 
advances in medical treatment of UC, 25-30% of patients will require surgery 
at some point in their life. The cumulative 10-year colectomy rate is about 
10% (Solberg et al. 2009). The two main options for surgical treatment for 
UC are panproctocolectomy with formation of an end ileostomy and 
restorative panproctocolectomy (RPC) with an ileal pouch-anal anastomosis 
(IPAA). The latter is the standard care in elective surgery for UC (Digass et 
al. 2012a). Panproctocolectomy with ileostomy is recommended for patients 
with impaired sphincter function, advanced age, significant comorbidities, or 
distal rectal cancer (Cohen et al. 2005). In some rare cases, a total colectomy 
with an ileorectal anastomosis is an option.  
 
Surgery in CD should be limited to the disease-related complications, such as 
strictures and fistulae, and emergencies, including perforations, intestinal 
obstruction, and bleeding. Surgery is the inevitable outcome for 
approximately 50% of patients with ileocaecal CD in the first 10 years after 
diagnosis, and all CD patients have a 70-80% lifetime risk of surgery (Carter 
et al. 2004). In localized colonic disease, limited resection of the affected 
segment is advised. However, in multi-segment colonic disease a subtotal 
colectomy with ileorectal anastomosis should be considered. Ileal pouch-anal 
anastomosis is not usually recommended in CD due to a high risk of 
complications and pouch failure. In ileal CD, stricturoplasty plays a central 
role. Although immunosuppressants have been used more frequently during 
the last 25 years, no significant decrease in surgery rates has been reported 
(Cosnes et al. 2005, Domenech et al. 2010). Even during the era of TNFα-
blocking therapy, findings for the need for of surgery have been controversial 
(Nguyen et al. 2011, Ehteshami-Afshar et al. 2011). A majority of patients 
achieve symptom relief after primary surgery, however, up to 44% of patients 
have needed second surgery during a 7-year follow-up (Larson and 
Pemberton 2004). Surgery should be considered a treatment option for CD 
patients and should be discussed with patients at an early stage (Dignass et 
al. 2010).  
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AIMS OF THE STUDY 
The aims of Studies I-IV were as follows: 
 
1. To determinate how often deep remission is achieved in IBD patients 
on TNFα-blocking therapy in everyday clinical practice (Study II). 
This information is essential when considering the possibility of 
discontinuing TNFα-blocking therapy in IBD patients.  
 
2. To assess the relapse rate and predictive factors for relapse after 
cessation of maintenance therapy with TNFα-blocking agents in IBD 
patients in deep remission (Study III). 
 
3. To evaluate the role of fecal calprotectin  
in predicting disease outcome of patients on TNFα-blocking 
therapy (Study I). 
in monitoring IBD patients after stopping TNFα-blocking 
therapy once patients attain deep remission (Study IV).  
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PATIENTS AND METHODS 
1 Patients 
 
1.1 Retrospective studies (I and II) 
 
1.1.1 Patients in Study I 
 
This study included all patients treated during the period April 2005 to April 
2010 at the Division of Gastroenterology, Helsinki University Central 
Hospital, for active luminal disease who had an elevated FC level at baseline 
and a documented FC concentration after induction with TNFα-blocking 
agents. Data were analyzed retrospectively for 60 IBD patients (34 CD, 26 
UC/IBDU). For induction patients received IFX 5 mg/kg either at weeks 0, 2, 
and 6 or at weeks 0 and 8 (16 CD, 26 UC) or ADA 160 mg at week 0, 80 mg at 
week 2, and thereafter 40 mg every other week or 80 mg at week 0 and 
thereafter 40 mg every other week (18 CD). After the induction, anti-TNF 
therapy was continued in all responders as a scheduled maintenance therapy 
for at least one year if not relapsing earlier. Based on the post-induction FC 
concentration, patients were grouped as normal post-induction FC (FC < 100 
μg/g) or elevated post-induction FC (FC ≥ 100 μg/g).  
 
1.1.2 Patients in Study II 
 
The data were collected retrospectively at eight gastroenterological units in 
Finland. We included 252 IBD patients (183 CD, 62 UC, and 7 IBDU) treated 
with a scheduled anti-TNF therapy for at least 11 months during 2010 and 
2011. Altogether 126 CD patients (69%) and 63 UC/IBDU (91%) patients 
were on concomitant immunomodulators (azathiprine, 6-mercaptopurine, or 
metotrexate). An ileocolonoscopy was mandatory. Because of its small size, 
the subgroup IBDU with 7 patients was included in the UC group. Only 20% 
(37 patients) of CD patients were treated for fistulizing disease, and the 
remaining 79% (145 patients) for luminal CD. In addition, in two patients 
with pediatric CD onset, the main indication for TNFα-blocking therapy had 
been delayed growth. Of patients with UC or IBDU, 45% (n=35) had a 
steroid-refractory disease and 55% (n=38) a steroid-dependent disease.  
 
Clinical characteristics of patients from Studies I and II are shown in Table 
14. 
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Table 14. Patient characteristics in Studies I and II. 
 
 Study I 
n=60  
(CD 34, UC 26) 
Study II 
n=252 
(CD 34, UC 62, IBDU 7) 
Sex, male/female DC: 19/15 
UC: 9/17 
DC: 85/98 
UC: 37/25 
IBDU: 5/2 
 
Age at diagnosis,  
years, median (range) 
CD: 21 (12–50) 
UC: 26 (16–46) 
CD: 21 (2–57) 
UC: 25 (8–72) 
IBDU: 18 (17–65) 
 
Age at induction,  
years, median (range) 
CD: 30 (19–52) 
UC: 29 (18–57) 
CD: 32 (12–69) 
UC: 31 (13–75) 
IBDU: 27 (22–68) 
 
Duration of disease,  
years, median (range) 
CD: 7 (1–27) 
UC: 3 (1–24) 
CD: 8 (<1–33) 
UC: 5 (<1–34) 
IBDU: 5 (<1–9) 
Localization of CD, n (%)   
 Ileum (L1) 7 (20.5%) 14 (8%) 
 Colon (L2) 
Ileocolon (L3) 
Upper GI 
L1 + upper GI 
L2 + upper GI 
L3 + upper GI 
7 (20.5%) 
17 (50%) 
1 (3%) 
1 (3%) 
0 
1 (3%) 
55(30%) 
106 (58%) 
0 
2 (1%) 
2(1%) 
4 (2%) 
Behavior of CD, n (%)   
 Inflammatory (B1) 9 (26%) 86 (47%) 
 Stricturing (B2) 16 (47%) 45 (25%) 
 Penetrating (B3) 
B1 + perianal disease 
B2 + perianal disease 
B3 + perianal disease 
 
2 (6%) 
4 (12%) 
1 (3%) 
2 (6%) 
20 (11%) 
11 (6%) 
13 (7%) 
8 (4%) 
Localisation of UC/IBDU, n (%)   
 Pancolitis 3 (12%) 45 (65%) 
 Proctosigmoiditis 
Proctitis 
23 (88%) 
0 
24 (35%) 
0 
   
Current smoking; no/yes CD: 25/9                       
UC: 23/3 
 
Anti-TNF therapy used, n (%)   
 Infliximab 42 (70%) 177 (70%) 
 Adalimumab 18 (30%) 75 (30%) 
CD = Crohn’s disease; UC = ulcerative colitis; IBDU = inflammatory bowel disease unclassified 
GI = gastrointestinal 
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1.2 Prospective studies (III and IV) 
 
1.2.1 Patients in Study III 
 
Between February 2010 and June 2013, 52 adults with IBD (17 CD, 35 
UC/IBDU) were recruited to this prospective multicenter study. All patients 
had been treated with TNFα-blocking therapy for at least 11 months and were 
in DR, i.e. clinical, endoscopic, and FC-based (<100 μg/g) remission, at 
inclusion. In addition, all patients had been in corticosteroid-free remission 
over the 6 months previous to study inclusion. Of the patients, 13 CD (76%) 
and 30 UC/IBDU (85%) were on concomitant immunomodulators. Patients 
with a history of escalation of TNFα-blocking agents during the previous 6 
months, perianal disease with no other effective medication available, history 
of relapse after TNFα-blocking agent withdrawal, severe arthritis as a 
concomitant indication for TNFα-blocking therapy, and pregnancy were 
excluded. Follow-ups with assessment of clinical activity were performed 
every 4 weeks up to 6 months and thereafter every second month until 
relapse orend of the study. In case of relapse, monitoring continued up to 12 
months after the restart of treatment. Endoscopic assessment of disease 
activity was performed at 4 and 12 months after drug withdrawal. Patients 
were asked to provide a stool sample for FC and blood samples for 
hemoglobin, white blood cell count, platelet count, and CRP levels at baseline 
and at 2, 4, 8, and 12 months after withdrawal. During the prospective 
follow-up the maintenance therapy was unaltered.  
 
1.2.2 Patients in Study IV 
 
Of the 52 patients in Study III, 49 (16 CD, 33 UC/IBDU) participated in 
Study IV. Three patients (one CD, two UC) were excluded due to lack of 
follow-up FC samples. 
 
Clinical characteristics of patients from Studies III and IV are shown in 
Table 15. 
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Table 15. Patient characteristics in Studies III and IV. 
 
 Study III 
n=52  
(CD 17, UC/IBDU 
35) 
Study IV 
n=49 
(CD 16, UC/IBDU 33) 
Sex, male/female CD: 8/9       
UC/IBDU: 20/15 
CD: 85/98       
UC/IBDU: 37/25    
Age at diagnosis, years, median (range) CD: 22 (13–42) 
UC/IBDU: 26 (8–45) 
CD: 23 (13-42) 
UC/IBDU: 26 (8-45) 
Age at induction, years, median (range) CD: 32 (15–52) 
UC/IBDU: 32 (13–58) 
CD: 32 (15-52) 
UC/IBDU: 32 (13-58) 
Duration of disease, years, median (range) CD: 10 (3–26) 
UC/IBDU: 6 (1–35) 
CD: 9 (3-25)             
UC/IBDU: 6 (1-35) 
Localization of CD, n (%)   
 Ileum (L1) 
Colon (L2) 
Ileocolon (L3) 
1 (6%) 
4 (24%) 
12 (70%) 
1 (6%) 
4 (25%) 
11 (69%) 
 
Behavior of CD, n (%) 
  
 Inflammatory (B1) 11 (65%) 10 (63%) 
 Stricturing (B2) 4 (25%) 4 (25%) 
 Penetrating (B3) 
B1 + perianal disease 
B2 + perianal disease 
B3 + perianal disease 
 
1 (6%) 
0  
1 (6%) 
0  
1 (6%) 
0  
1 (6%) 
0  
Localization of UC/IBDU, n (%)   
 Pancolitis 20 (57%) 19 (65%) 
 Proctosigmoiditis 
Proctitis 
15 (43%) 
0 
14 (35%) 
0 
   
Current smoking: no/yes CD: 25/9                      
UC: 23/3 
CD: 12/4                         
UC: 29/4 
Duration of TNFa-blocking therapy 
before cessation of therapy, months, 
median, (range) 
              Infliximab 
             Adalimumab 
 
 
CD: 32 (11–72)        
UC/IBDU: 14 (11–78)  
CD: 26 (16–36) 
 
 
CD: 34 (11–70)    
UC/IBDU: 12 (11–77)     
CD: 26 (16–36) 
History of anti-TNF therapy, n (%)   
 Infliximab CD: 12 (71)        
UC/IBDU: 35 (100) 
CD: 11 (69)         
UC/IBDU: 33 (100) 
 Adalimumab CD: 5 (29) CD: 5 (31) 
CD = Crohn’s disease; UC = ulcerative colitis; IBDU = inflammatory bowel disease unclassified 
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2 Methods 
 
2.1 Clinical scoring 
 
In retrospective Study I, clinical activity indices were mostly collected from 
research files, but in some cases they were scored according to data available 
in patient records. Clinical disease activity was assessed with HBI (Harvey 
and Bradshaw 1980) in CD and with partial Mayo score (total Mayo score 
without endoscopy) (D’Haens et al. 2007) in UC at baseline, after induction 
with anti-TNF antagonists, and at one year. In Study II, the physicians’ global 
assessment (PGA) score was used for assessment of disease activity at the 
time of ileocolonoscopy. Patients with GI symptoms indicating active IBD 
scored 1 and nonsymptomatic patients 0. In prospective studies III and IV, 
HBI served as a measure for clinical disease activity in CD and partial Mayo 
score in UC/IBDU. In Studies I, III, and IV, clinical remission was defined as 
HBI < 4, mildly active disease as HBI 4-7, a moderately active disease as HBI 
8-16, and severely active disease as HBI ≥ 17 (Best et al. 2006). Clinical 
relapse was defined as HBI ≥ 8 or an increase of > 3 points in HBI to at least 
5 points. In partial Mayo score, 0 was defined as remission, 1-3 as mildly 
active disease, 4-6 as moderately active disease, and > 7 as severely active 
disease. With 0 was defined as remission, clinical relapse was defined as a 
partial Mayo score ≥ 3 (Schroeder et al. 1987). 
 
2.2 Endoscopic scoring 
 
In CD, endoscopic findings were graded according to the Simple Endoscopic 
Score for Crohn’s disease (SES-CD) (Dapero et al. 2004), and in UC 
according to the Mayo endoscopic score (D’Haens et al. 2007). SES-CD 0-2 
was defined as remission, 3-6 as mildly active disease, 7-15 as moderately 
active disease, and ≥16 as severely active disease (Moskovitz et al. 2007). For 
the Mayo endoscopic subscore, endoscopic findings were graded as normal 
(0), mild (1), moderate (2), or severe (3); a subscore of 0-1, was defined as 
remission and a subscore of >2 as active disease (D’Haens et al. 2007). 
Ileocolonoscopies were preformed and endoscopic findings scored in 
participating units as part of routine clinical practice. 
 
2.3 Histological scoring (II and IV) 
 
Ileocolonoscopies were performed in all four studies and random biopsy 
specimens were taken from five different segments: the ileum, the right, 
transverse, and left colon, and the rectum. During all endoscopies biopsies 
were collected from the most severely diseased areas or, if no lesions were 
found, from random sites of each segment. In Study II, we graded 
histological findings according to the most severely diseased areas, 0 
representing normal areas and 1 active inflammation. In Study IV, a single 
experienced GI pathologist scored the histological findings according to the 
scoring system developed for histological abnormalities in CD (D’Haens et al. 
1998) and UC (D’Haens et al. 2007). The scoring system is described in detail 
in Study IV.  
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2.4 Fecal calprotectin and blood tests 
 
Fecal calprotectin was measured by a quantitative enzyme immunoassay (the 
CALPRO® calprotectin ELISA test (ALP; Calpro AB, Lysaker, Norway)) and 
FC concentration < 100 µg/g was quoted as normal (von Roon et al 2007). 
Blood tests, such as blood count, ESR, and CRP, were performed as part of 
routine clinical follow-up and determined by normal laboratory values.  
 
2.5 Quality of life (III) 
 
Questionnaires on the quality of life were used in Study III. All patients were 
asked to fill in the Inflammatory Bowel Disease Questionnaire (IBDQ) and 
15D at baseline, at the time of possible relapse, and at the time of the 
ileocolonoscopies. The IBDQ was used under license from McMaster 
University, Hamilton, Ontario, Canada. The IBDQ and 15D are described in 
detail in Study III. 
 
2.6 Statistics 
 
For data analyses in all studies, we used Statistical Package for the Social 
Sciences (SPSS version 17.0 and PASW 18) for Windows software (SPSS, 
Chicago, IL, USA). The results were given as percentages, as median and 
range, or as mean and standard deviation (SD). In Study I, a power 
calculation was performed. The Wilcoxon signed-rank test was used to test 
the differences between related variables (Study I), and the Mann-Whitney 
U-test (Studies I-IV) and T-test (Studies III and IV) to assessthe differences 
between independent variables. Fisher’s exact test (Studies I and III) was 
used to determine differences in binary variables, and the Chi square test 
(Study II) to determine differences between categorical variables. Normality 
of the continuous variables was evaluated with the Kolmogorov-Smirnov test 
(Study III). The Cox regression of proportional hazards was used to calculate 
univariate hazard ratios for categorical and continuous variables (Study III). 
Kaplan-Meier survival analysis served to estimate relapse-free survival rates, 
and the log rank test to determine differences between the groups (Study III 
and IV). Receiver-operator characteristic (ROC) curve analysis was used to 
calculate the cut off value for FC to predict the outcomes (Study I and IV). 
The optimized cutoff level offered the best combination of sensitivity and 
specificity. In Study IV, we used the general estimating equation model to 
calculate the estimated FC level at relapse in the various groups. FC values 
were calculated at individual time-points and presented as medians and 
range. Significance was set at p < 0.05. 
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2.7 Ethical considerations 
 
The study protocols of Studies III and IV and all documents were approved 
by the Ethics Committee of Helsinki University Central Hospital (number 
348/13/03/01/2009) and the ethics committees of each participating 
university central hospital. No ethics committee approval was sought for 
Studies I and II because these studies comprised merely a retrospective 
reviewing of patients' medical records. Research study permission number 
195/2009 was received from the Department of Medicine, Helsinki 
University Central Hospital in December 2009. For Studies III and IV, all 
patients gave their written consent prior to participation.  
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RESULTS 
1 Achievement of deep remission in IBD with TNFα-blocking 
therapy  
 
Study II 
Of 252 patients, 168 (67%) were in clinical remission and 122 (48%) in DR 
after a median of 23 months of TNFα-blocking therapy (range 11-147). Up to 
63% (116/183) of CD patients and 75% (52/69) of UC patients achieved 
clinical remission, whereas 43% (79/183) of CD patients and 62% (43/69) of 
UC patients achieved DR (Figure 1). No significant difference was found in 
achieving clinical remission between CD and UC patients (p=0.072), but UC 
patients achieved DR significantly more often than CD patients (p=0.007). 
Of all CD patients in DR, 75% were also in histological remission, whereas in 
UC the rate was 93% (p=0.001). Concomitant histological remission with DR 
occurred in 59 CD patients (32%) and 40 UC patients (58%). The significance 
of combination therapy with azathioprine, 6-mercaptopurine, and 
methotrexate on the DR rates was also evaluated; however, no significant 
differences were found in inducing DR in patients on combination therapy 
compared with patients on monotherapy (all patients p = 0.214, CD p = 
0.845, UC p = 0.107). CD patients receiving IFX achieved DR slightly more 
often than patients on ADA therapy (46% vs. 39%), but because of the 
relatively heterogeneous study population, no direct comparison between the 
two regimens was conducted.  
 
Based on clinical judgement, in 43% (53/122) of patients in deep remission 
TNFα-blocking therapy was withdrawn. Discontinuation of TNFα-blocking 
therapies was tried for the first time in all of these patients. In the remaining 
69 patients (57%) TNFα-blocking therapy was continued because of a disease 
with no other effective medication available (n = 19), fistulating disease (n = 
6), concomitant rheumatoid disease (n = 4), high FC level (n = 6), history of 
severe disease (n = 19), or previous unsuccessful withdrawal of TNFα-
blocking therapy. 
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Figure 1. Achievement of clinical and deep remission in IBD with TNFα-
blocking therapy.  
 
 
 
 
 
2 Discontinuation of TNFα -blocking therapy in IBD 
 
Study III 
A total of 52 patients (17 CD, 30 UC, 5 IBDU) were recruited in Study III.  
Because of its small size, the subgroup IBDU with five patients was combined 
with the UC group. During the follow-up phase one UC patient dropped out 
at 6 months while in clinical remission. Of the remaining 51 patients, 5/17 
(29%) CD and 12/34 (35%) UC/IBDU patients relapsed after a median 
follow-up of 13 (range 12-15) months and 34 of patients (67%) remained in 
clinical remission (Figure 2). Twenty-nine (85%) of these patients were also 
in endoscopic remission. In relapsers, ten patients (19%) (3 CD, 7 UC) 
experienced both clinical and endoscopic relapse, two CD patients (4%) a 
nonsymptomatic severe endoscopic relapse, and five UC patients (10%) a 
clinical relapse with mild endoscopic activity (Mayo score 1) not fulfilling the 
predefined criteria for endoscopic relapse (endoscopic Mayo score ≥ 2), but 
were considered relapsers because of severe clinical symptoms. Relapses 
occurred at a median of 6 (range 2.5-15) months after cessation of TNFα-
blocking therapy. Interestingly, no significant difference was found between 
CD and UC/IBDU in the relapse rate (p = 0.896). 
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Figure 2. Flow chart of Study III (data adapted from Molander et al 2013). 
In this study, we also evaluated the odds of a reduction in quality of life 
scores in relapsers. As expected, both 15D score (0.955 [0.879 – 1.0] versus 
0.853 [0.745 - 0.938], p < 0.001) and IBDQ score (193 [164 - 223] versus 142 
[102 - 183], p < 0.001) were significantly lower at relapse than at baseline. 
Both scores were equal at baseline and at 12 months after the restart of 
TNFα-blocking therapy (p = 0.705 and p = 1.0, respectively). 
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Risk factors for relapse 
The risk factors were calculated by the Cox model. No specific factor, such as 
gender, age at diagnosis, disease duration, localization or behavior of the 
disease, previous surgery, smoking, chosen TNFα-blocking therapy, duration 
of TNFα-blocking therapy, concomitant medications, quality of life score, or 
haemoglobin or CRP levels at the time of discontinuation, was found to 
predict the relapse (Table 16).  
 
 
 
 
Table 15. Risk factors 
      
Variable 
Relapse Remission HR 95% CI 
P – value 
 (n=17) (n=34) 
 
Lower/ 
Upper 
Male sex (%) 9 (53) 19 (56%) 0.89 0.34/2.31 0.808 
Positive family history 2 (12%) 8 (24%) 0.44 0.10/1.92 0.275 
Age at diagnosis,  
median years (range) 
22 (8-44) 26 (16-45) 0.98 0.92/1.03 0.387 
Age at induction of TNFα-
blocking therapy, median years 
32 (13-52) 32 (17-58) 0.98 0.94/1.03 0.510 
Duration of disease, median 
years (range) 
8 (2-26) 7 (1-35) 1.01 0.95/1.07 
0.816 
Duration of TNFα-blocking 
therapy,     
   
mean months (range) 26 (10-71) 22 (10-77) 1.01 0.98/1.03 0.572 
Localization of  UC 
     
    Proctosigmoiditis 5(45%) 10 (45%) 1.00 
  
    Extensive colitis 6 (55%) 12 (55%) 0.99 0.30/3.23 0.981 
Localization of CD 
     
    Ileum 1 (170%) 
 
1.00 
 
0.365 
    Ileocolon 4 (67%) 9 (75%) 0.20 0.02/1.98 0.167 
    Colon 1 (17%) 3 (25%) 0.18 0.01/3.23 0.247 
Disease behavior (Mb Crohn)                          
     
    Inflammatory (B1) 5 (83%) 7 (58%) 1.00 
 
0.970 
    Stricturing (B2) 1 (17%) 3 (25%) 0.58 0.07/4.99 0.622 
    Penetrating (B3) 
 
1 (8%) 
   
    B2 + perianal 
 
1 (8%) 
   
Previous surgery 1 (6%) 7 (21%) 0.30 0.04/2.25 0.240 
Smoker or previous smoker 4 (24%) 16 (47%) 0.43 0.14/1.33 0.144 
TNFα-blocking therapy used 
     
    Infliximab 16 (94%) 30 (88%) 1.00 
  
   Adalimumab 1   (6%) 4   (12%)  0.56 0.07/4.23 0.574 
Concomitant 
immunosuppressive therapy 
14 (82%) 29 (85%) 0.91 0.26/3.16 0.877 
CRP at discontinuation, 
 mean (range) 
2.6 (1-3) 3.8 (1-16) 0.81 0.57/1.15 0.231 
Hemoglobin at 
discontinuation; mean (range) 
142 (127-171) 138  (109-167) 1.02 0.98/1.05 0.350 
IBDQ at discontinuation, 
mean (range) 
193 (164-223) 197  (151-219) 0:99 0.96/1.02 0.425 
15D at discontinuation, 
 mean (range) 
0.96 (0.879-1) 0.95 (0.844-1) 3.72 0.00/4.90 0.827 
HR = hazard ratio; CD = Crohn’s disease; UC = ulcerative colitis; CRP = C -reactive protein; IBDQ = 
inflammatory bowel disease questionnaire 
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Restart of TNFα-blocking therapy 
TNFα-blocking therapy was restarted in 15 patients and they were followed 
up for approximately 12 (range 9-14) months. No infusion reactions or 
serious adverse events were reported during the follow-up. One UC patient 
without response to restart of infliximab underwent colectomy less than 2 
months after the restart of infliximab. At 3 months, 14 patients (14/15, 93%) 
were in clinical remission, and at 12 months all four CD patients and nine of 
ten UC patients (90%) were in clinical remission. Endoscopic assessment of 
disease activity was performed on three CD patients and nine UC patients at 
12 months. Ileocolonoscopies showed mild activity in all three CD patients, 
but endoscopic remission in all UC patients. No tendency towards an 
increase in clinical or endoscopic activity indices or a decrease in IBDQ or 
15D scores before the relapse was found.  
 
 
3 Long-term treatment response and outcome after cessation of 
TNFα-blocking therapy 
 
3.1 Fecal calprotectin as a predictor of long-term treatment 
response 
 
Study I 
Sixty patients with elevated baseline FC (median 810 µg/g, range 103–12.258 
µg/g) were recruited. After induction with TNFα-antagonists, median FC 
level decreased to 97 µg/g (range 0–5859, p < 0.001). Patients were divided 
into two groups based on FC levels after induction therapy (Figure 3). Of 60 
patients, 31 (52%) had normal FC after induction therapy, whereas 29 (48%) 
had an elevated FC. In this latter group, patients in clinical remission had 
lower median FC concentrations after induction therapy than those with 
clinically active disease (204 µg/g, range 116–670 vs. 496 µg/g, range 123–
2896, p= 0.025). In the normal FC group, after induction therapy, 27/31 
(84%) showed FC decline more than 75% and up to 82% of these patients 
were in clinical remission at one year, whereas only 38% of patients with an 
elevated post-induction FC had achieved clinical remission (p = 0002). At 
approximately one year, 48 patients were on maintenance therapy. Of these 
48 patients, 37 (27 CD, 10 UC) were in clinical remission and 8 (7 CD, 1 UC) 
had clinically active disease, CD patients significantly more often than UC 
patients (p = 0.001).  Three UC patients underwent colectomy. Of 31 patients 
in the normal post-induction calprotectin -group, 26 (84%) were in clinical 
remission, whereas only 11 patients (38%) in the elevated post-induction FC -
group were in clinical remission (p<0.0001) (Figure 4). Of 48 patients, 25 
had provided a stool sample for FC at one year, 17 in the normal post-
induction FC group and 8 elevated in the post-induction FC group. In the 
normal post-induction FC group, 13 patients (76%) showed a normal FC 
value, whereas only 4 patients (50%) had a normal FC in the elevated post-
induction FC group. Endoscopic reassessment was performed for 38 patients 
(27 CD, 11 UC) at one year. Endoscopic remission (SES-CD < 3 or Mayo 
endoscopic subscore ≤ 1) was discovered more often in patients with a 
normal post-induction FC; the difference was not significant (17/23, 74% 
versus 7/15, 47%). Moreover, in the normal post-induction FC group, 17 
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patients (62%) were in both clinical and endoscopic remission, while only 
seven patients (33%) achieved clinical and endoscopic remission in the 
elevated post-induction FC group. 
 
 
 
 
 
 
 
 
 
Figure 3. Flow chart of Study I (data adapted from Molander et al. 2012). 
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Figure 4. Kaplan-Meier survival curve showing the risk of relapse in 
relation to FC levels below and above 100 µg/g. P value was calculated by the 
log-rank test (p<0.001). 
 
  
 
The ROC curve in Study I was constructed to predict the long-term outcome 
according to the post-induction FC level. The FC value of 139 µg/g, with a 
sensitivity of 72%, a specificity of 80%, and AUC 0.838 [0.724-0.952]), was 
optimized as the best cut-off for predicting relapse at one year. Chosen anti-
TNF antagonists (OR 0.35; 95% CI 0.10–1.23, p = 0.147), smoking (OR 1.19, 
95% CI 4.32–0.33, p = 1), or gender (OR 0.33; 95% CI 0.11–1.00, p = 0.064) 
did not have a significant impact on the clinical remission rate. An additional 
ROC curve was constructed to predict the positive outcome according to 
decline of the FC from baseline to post-induction assessment. A decline of 
88% in FC gave the maximum sensitivity (87%), specificity (65%), and AUC 
(0.771, 0.652–0.890) for predicting clinical remission at one year.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Calprotectin  
>100 m/g   
<=100m/g   
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3.2 Fecal calprotectin as a predictor of relapse 
 
Study II 
In Study II, FC measurements were available for 163 of 252 patients. Median 
FC level was significantly lower for the 79 patients in DR than for the 84 
patients with active disease (50 µg/g, range 1–722 vs. 288 µg/g, range 6–
4190, p < 0.0001). Of all patients, FC was normal (<100 µg/g) in 88. In the 
DR, 63 patients (72%) had normal FC levels, but in the active disease group, 
FC was normal in only 16 patients (21%) (p < 0.0001). 
 
Study IV 
Study IV included 49 patients in deep remission with TNFα-blocking 
therapy. After discontinuing of anti-TNF agents, 34 patients (69%, 12 CD, 22 
UC) remained in remission during the one-year follow-up and 15 (31%, 4 CD, 
11 UC) experienced either clinical or endoscopic relapse (9 patients; 2 CD, 7 
UC), only endoscopic relapse (2 CD), or clinical relapse with mild endoscopic 
activity (4 UC). No clinical relapses without signs of endoscopic activity were 
found.  
 
FC concentrations and relapse risk (Study IV) 
Stool samples for FC measurements were collected to evaluate whether 
elevated FC after discontinuing TNFα-blocking therapy can predict clinical or 
endoscopic relapse.  A significantly higher median baseline FC concentration 
was seen in patients with relapse already 6 (120 µg/g, 0–431, n = 6, p = 
0.0029), 4 (108 µg/g, 7–650, n = 8, p = 0.0056), and 2 months (120 µg/g, 0–
1867, n = 15, p = 0.0014) before the clinical relapse. Differing from the 
patients with stable remission, once FC was elevated in the group of patients 
with relapse, it remained elevated until clinical or endoscopic relapse 
occurred. In patients with stable remission, the elevation in FC concentration 
appeared to be transient in the majority (18/22, 82%). With ROC analysis, 
we evaluated the best cut-off value for FC to predict relapse. The cut-off of > 
140 µg/g could predict relapse with 79% specificity and 53% sensitivity 6 
months before the relapse. Furthermore, ROC analyses indicated that FC > 
200 µg/g measured 2-4 months before clinical relapse and FC > 199 µg/g 
measured 4-6 months before relapse could predict relapse with 84% and 94% 
specificity and 50% and 53% sensitivity, respectively. No significant 
difference was found in relapse rate with patientswho had FC 50 µg/g or FC 
50–100 µg/g at baseline (p = 0.325). The general estimating equation model 
showed that at relapse patients with relapse had higher FC levels (estimated 
199 µg/g, 95% CI 103–386 µg/g) than nonrelapsers at the end of the follow-
up (49 µg/g, 95% CI 35–69 µg/g). 
 
Fecal calprotectin and histological findings (Study IV) 
In Study IV, we also evaluated the correlation of FC and histological findings, 
as well as the impact of histological inflammation on relapse risk. Endoscopic 
assessment was performed in all 49 patients at baseline, in 41 patients at 4 
months, and in 31/34 patients still in remission at 12 months. At baseline, 40 
patients (82%) showed no signs of histological inflammation in specimens, 
whereas mild infiltration of neutrophils in the lamina propria or in the 
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epithelium appeared in four patients (8%) and moderate inflammation in 
five patients (10%). No significant difference was found in the relapse rate in 
patients with acute or chronic inflammatory infiltrate at baseline compared 
with those who had no signs of inflammation in biopsy specimens (p = 
0.221). Since there is no validated histological score for remission or relapse, 
we defined histological remission as no neutrophils in the lamina propria or 
in the epithelium.  Histological relapse was defined as the sum of these two 
scores ≥ 1. The median histology score in patients who relapsed was equal to 
that in patients who remained in remission (p = 0.324). Twelve months after 
cessation of TNFα-blocking therapy, the majority (16/18, 89%) of patients 
with normal histological findings in specimens had normal (<100 µg/g) FC 
concentration (34 µg/g, range 0–178), whereas only 40% of patients with 
mild inflammatory activity had normal FC levels (156 µg/g, range 57–340, n 
= 6). Comparing the levels of FC in patients with or without inflammatory 
activity, FC was significantly higher in active disease (p = 0.016). 
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DISCUSSION 
1 Concept of deep remission and TNFα-blocking therapy in IBD 
 
In the era of TNFα-blocking therapy, MH has become a generally accepted 
and desirable endpoint in the treatment of IBD. In addition, it seems to be an 
important predictor of treatment outcome. However, it is still unresolved 
whether complete MH i.e. deep remission, offers better treatment outcome 
than partial MH. Nevertheless, the ability of TNFα-blocking therapy to 
induce MH has been in great interest over the past decade. The results of our 
study demonstrate that during scheduled TNFα-blocking therapy in everyday 
clinical practice about half of IBD patients may achieve DR, and nearly 40% 
of patients achieve concomitant clinical, endoscopic, FC-based, and 
histological remission.  
 
The post-hoc data of the EXTEND trial on DR in CD demonstrated that DR, 
defined as a combination of clinical remission (CDAI <150) and complete 
MH, was achievable in some 19% of patients by week 52 (Rutgeerts et al. 
2012). Early MH was not a predictor of long-term MH in this study. 
However, sub-analysis of the EXTENT trial showed that DR at week 12 was 
associated with fewer hospitalizations, better quality of life, and lower 
healthcare costs during the first year of therapy (Colombel et al. 2011). 
Differing from the EXTEND trial, two Finnish studies have demonstrated 
that endoscopic findings at three months after the start of TNFα-blocking 
therapy are highly predictive of favorable outcome at one year in patients 
with luminal CD (af Björkesten et al. 2011, 2013). In both of these studies, 
endoscopic remission achieved at three months was associated with a 
significantly higher likelihood of endoscopic remission with scheduled 
maintenance therapy at one year; up to 70% and 90% of endoscopic anti-
TNF induction responders were in endoscopic remission at one year. Some 
differences between the EXTEND trial and real life experiences may be 
explained by the strict inclusion criteria of the study and also by the 
exclusion from primary analysis of patients switched to the open label 
treatment group. The CHARM study, with no endoscopic data available, 
demonstrated a steroid-free clinical remission rate at week 56 for 29% of 
patients and also fewer hospitalizations and surgery (Colombel et al. 2009). 
In addition, the CHARM trial indicated that patients with a shorter disease 
duration presented better response rates to TNFα-blocking therapy. Similar 
results were shown also in the EXTEND trial. Response to treatment in early 
CD has been demonstrated to be more effective and associated with a better 
long-term outcome than later treatment (Føslier et al. 2007, D’Haens et al. 
2008, Colombel et al. 2010, Ha et al. 2010, Baert et al. 2010). Patients with a 
disease duration of less than two years have shown the most favorable 
outcome (Sandborn et al. 2012a). 
 
Several clinical trials and population-based studies have revealed that also 
patients on IFX therapy who achieve MH have better outcomes than those 
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who do not achieve MH (Rutgeerts et al. 2006, Lichtenstein et al. 2002 and 
2004, Baert et al. 2010, D’Haens et al. 2002, Schnitzler et al. 2009). The 
ACCENT 1 endoscopic substudy demonstrated complete MH in nearly half of 
the patients by week 52, leading to significant reductions in the number of 
hospitalizations, surgeries, and days in intensive care units, compared with 
patients with only transient healing or no healing at all (Rutgeerts et al. 
2006). Lichtenstein and coworkers (2002 and 2004) showed that patients 
achieving MH on maintenance therapy with IFX experienced fewer disease-
associated complications, such as hospitalizations and surgery, and had a 
better quality of life. Similar results were also presented by Schnitzler and his 
colleagues (2009). Complete MH has also been demonstrated to lead to 
significantly higher steroid-free remission rates in patients with early-stage 
CD, for as long as four years after start of therapy (Baert et al. 2010). The 
efficacy of TNFα-blocking therapy in UC is mainly based on the ACT 1 trial. 
Moreover, Sandborn and coworkers (2009) demonstrated that IFX-treated 
patients achieving MH already at week 8 were less likely to have colectomy at 
week 54. Scheduled maintenance therapy with IFX 5 mg/kg resulted in MH 
in about 42% of patients by week 54 and with IFX 10 mg/kg in 47% 
(Rutgeerts et al. 2006, 2009). However, the decision on whether or not to 
continue the therapy, was based on clinical response (Hanauer et al. 2002). 
Regardless of some limitations in our study, the results of Study II reflect 
well the situation in clinical practice. In CD, nearly half of the patients in the 
IFX group and some 40% in the ADA group achieved DR. In UC, 63% of 
patients on IFX maintenance therapy achieved DR. The clinical remission 
rates were even higher. IFX therapy resulted in clinical remission in 66% of 
CD patients and 77% of UC patients, whereas ADA therapy induced clinical 
remission in 60% of CD patients. Based on existing data, the achievement of 
DR might be the only way to altere the course of IBD. However, the concept 
of DR requires better validation.  
 
The impact of histological healing among IBD patients treated with TNFα-
blocking therapy is to some extent unknown. Histological changes tend to lag 
behind clinical and endoscopic improvement, therefore having very little 
clinical relevance in decision-making. Over a decade ago, Sandborn and 
coworkers (2002) did not recommend the assessment of histological disease 
activity as a treatment endpoint due to uncertainty in the significance of 
histological disease activity and the localization of CD inflammation as well 
as the potential for sampling error. By contrast, more recently, D’Haens and 
coworkers (2007) stated that histological remission should be considered a 
secondary endpoint, at least in clinical trials. Additionally, they 
recommended the use of the existing scoring system for histological 
abnormalities, if measurement of histological disease activity was desired. 
However, the well-defined and validated endpoints for histological remission 
should be developed. We were able to demonstrate that a lower FC 
concentration in patients with clinical and endoscopic remission was strongly 
associated with histological remission. Nevertheless, histological 
inflammation at the time of cessation of TNFα-blocking therapy did not 
predict relapse. Therefore, unfortunately, the assessment of histological 
activity seems to offer no extra value in evaluating the risk of relapse.  
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2 Discontinuation and re-initation of TNFα-blocking therapy in 
IBD 
 
In recent years, several studies have been published on the duration of 
remission after discontinuation of TNFα-blocking therapy, indicating that in 
some CD patients withdrawal of TNFα-blocking therapy is an reasonable 
option (Baert et al. 2010, Waught et al. 2010, Louise et al. 2012, Steenholdt 
et al. 2012, Rismo et al. 2013, Molnar et al. 2013, Farkas et al. 2013). 
However, the existing data suggest that if patients are followed long enough, 
eventually all patients will experience either clinical (Regueiro et al. 2010) or 
endoscopic relapse (Regueiro et al. 2010, Sorrentino et al. 2010, Steenholdt 
et al. 2012, Rismo et al. 2013). However, none of these studies has assessed 
endoscopic activity during the follow-up. In addition, in the widely cited 
STORI trial of 115 CD patients, endoscopic remission was not an inclusion 
criterion, and therefore 23% of baseline CDEIS values were ≥ 3 and 34% of 
patients had remaining ulcers, indicating ongoing inflammatory activity at 
the time of cessation of therapy. Furthermore, in some patients, baseline FC 
measurement was elevated, indicating disease activity. Many of the relapse 
risk factors shown in previous studies are associated with incomplete 
remission with ongoing inflammatory disease activity, which may explain the 
lower remission rate in earlier studies than in ours, which included only 
patients in deep IBD remission (Baert et al. 2010, Waught et al. 2010, Louise 
et al. 2012, Steenholdt et al. 2012, Rismo et al. 2013, Molnar et al. 2013, 
Farkas et al. 2013). Moreover, due to our stringent inclusion and exclusion 
criteria, all patients with moderate or severe perianal CD or with severe 
arthritis were excluded. In theory, these stringent criteria could explain the 
higher remission rate. However, this is unlikely, because also in the STORI 
trial, patients with predominantly fistulizing perianal disease without 
significant luminal disease, with active fistulizing disease, or with severe 
extraintestinal manifestations were excluded. Until now, only one study has 
been published on a longer follow-up after discontinuation of therapy. 
Waught and coworkers (2010) reported that 35% of CD patients remained in 
sustained clinical remission for nearly 7 years after stopping anti-TNF 
agents. The maintenance of remission in IBD patients after cessation of 
TNFα-blocking therapy might be explained by its typical relapsing-remitting 
course, with outcome dependent on the individual disease course and timing 
of therapy interruption resulting in long-term remission. Possibly, a patient 
will remain in remission because interruption of therapy may coincide with 
the naturally occurring phase of quiescence.  Thus, considering the 
immunological nature of IBD diseases, the development of mucosal immune 
dysregulation, i.e. weak immune response, by may also lead to long-term 
drug-free remission.  
 
To tailor the TNFα-blocking therapy, dose increase or shortening of the 
therapeutic interval is an accepted strategy for patients who have lost 
response to anti-TNF agents (Gisbert et al. 2009b), but no studies have been 
designed to evaluate whether the minimal effective dose of anti-TNF agents 
in all IBD patients is the one recommended by the manufacturer or whether 
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a lower dose could be equally effective. On the other hand, low drug dosages 
may be associated with low drug trough levels, may cause antibody 
formation, and furthermore may affect drug efficacy and cause adverse 
reactions. However, nowadays, it is recommended to treat CD with anti-TNF 
agents at an earlier phase of the disease course, when patients are more 
responsive because of low disease burden and lower dosage of anti-TNF 
might be effective as explored in rheumatoid arthritis and other 
rheumatologic diseases. 
 
To date, no widely accepted recommendations for discontinuing TNFα-
blocking therapy have been made. Based on earlier studies, many authors do 
not advocate stopping TNFα-blocking therapy in patients who respond to 
therapy with no side-effects (Clarke et al. 2012, Peyrin-Biroulet et al. 2012). 
However, for economic and safety reasons, clear recommendations for 
discontinuing TNFα-blocking therapy are needed. A multidisciplinary 
European expert panel (D’Haens et al. 2010) considered discontinuing 
TNFα-blocking therapy to be appropriate after 4 years, but also after 2 years 
if the patient were in DR. The results of our study, with up to 67% of IBD 
patients remaining in clinical remission during the 12-month follow-up, 
suggest that withdrawal of TNFα-blocking therapy could already be possible 
after one year of therapy when patients, especially UC patients, are in DR. 
 
The risk of immunization resulting in hypersensitivity reactions and loss of 
effect should be considered when restarting medication after a drug-
freeintermission. According to available data (Louise et al. 2012, Steenholdt 
et al. 2012, Molnar et al. 2013), retreatment with TNFα-blocking therapy is 
well-tolerated and effective. No hypersensitivity reactions have been 
reported. Also in our study, all but one patient with relapse achieved clinical 
remission or response and three-quarters of patients achieved endoscopic 
remission during a median follow-up of 12 months.  
 
 
3 Fecal calprotectin in monitoring TNFα -blocking therapy 
 
A need for a reliable surrogate marker in monitoring treatment outcomes in 
IBD has arisen, with endoscopic assessement being time-consuming, costly, 
and unpleasant for the patient. FC has been shown to be a reliable surrogate 
marker for MH in IBD (Tibble et al. 2000b, Røseth et al. 2004). Røseth and 
coworkers (2004) were the first to demonstrate that MH can be determined 
by assessment of FC in a simple stool sample. In IBD patients in clinical and 
FC–based remission (FC <50 µg/g), the endoscopic findings in all but one 
patient were normal, and the majority of patients had no inflammatory 
activity in biopsies. Also a prospective study of 77 CD patients showed a 
significant correlation between FC and CDEIS (p < 0.001) (Sipponen et al. 
2008b). The study concluded that FC is a useful surrogate marker for MH in 
CD patients receiving induction with TNFα-blocking agents, and FC < 200 
µg/g could serve as a cut-off for endoscopically inactive disease. A single FC 
measurement has been shown to predict clinical relapse in IBD patients with 
clinically quiescent disease in several other studies (Costa et al. 2005, D'Inca 
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et al. 2008, Gisbert et al. 2009a, Garcia-Sanchez et al. 2010). Moreover, 
recent meta-analysis demonstrated a pooled sensitivity of 78% and a 
specificity of 73% for FC in predicting IBD relapse, especially in ileocolonic 
and colonic CD and UC (Mao et al. 2012). Furthermore, a large retrospective 
cohort of CD patients provided compelling evidence that FC measurement 
could be used to predict disease course because FC concentrations were 
significantly higher in patients with progressive CD than in those without 
disease progression (Kennedy et al. 2013). In this study, a normal FC 
concentration after the induction therapy was shown to predict better clinical 
outcome at one year in patients with active luminal IBD. We were the first 
group to demonstrate the capacity of normal FC concentration after 
induction with TNFα-blocking agents to predict clinical and probably 
endoscopic remission after 12 months of maintenance therapy with TNFα-
blocking agents. These findings verify noninvasive FC test to be a useful and 
simple test in distinguishing endoscopically active disease from 
endoscopically inactive disease, and also in predicting relapse and disease 
outcome in quiescent IBD patients. Based on the available studies, it is not 
yet possible to set different cut-off values for CD and UC. 
 
To date, no uniform consensus exists on the cut-off value of FC that predicts 
relapse, hence several cut-off values for predicting relapse in clinically 
inactive IBD patients have been reported. D'Inca and coworkers (2008) 
demonstrated that FC level > 130 mg/kg (µg/g) predicts clinical relapse in 
UC and in colonic CD, whereas the study of Garcia-Sanchez and coworkers 
(2010) showed a 6-fold increase in relapse rate in one year in UC with FC > 
120 µg/g, and a 4-fold increase in CD with FC level > 200 µg/g at baseline. In 
a study published only as an abstract, normalization of FC was shown to 
correlate significantly with clinical response after anti-TNFα induction 
therapy. In that study, FC > 150 mg/kg (µg/g) after induction therapy 
showed an increased risk of relapse in one year. These findings are in line 
with our study, where an FC of 139 μg/g seems to predict relapse risk during 
TNFα -blocking maintenance therapy fairly well. The outcome was almost 
equal when comparing patients with normal FC level and those with 75% 
decline of FC level after induction. The best predictive value for decline of FC 
was 88%. It is therefore reasonable to consider both patients with a normal 
FC level and those with an FC decline over 88% as responders. In addition, 
we were able to demonstrate that FC < 140 μg/g after stopping TNFα-
blocking therapy indicates a relapse risk in asymptomatic patients already 6 
months before the clinical or endoscopic relapse occurs. These findings are in 
line with the preliminary data from the STORI trial, revealing that FC begins 
to increase 4–6 months before the clinical relapse. Nonetheless, rather than 
setting one cut-off value for all IBD patients, one should take into 
consideration the behavioral and localization of the disease as well as the 
patient history.   
 
While a single FC measurement has been shown to predict the relapse, De 
Vos and coworkers (2013) reported that two consecutive FC measurements > 
300 mg/kg (µg/g) is more specific than a single measurement for predicting 
relapse in UC patients receiving IFX as a maintenance treatment. In 
addition, nearly 80% of the patients in sustained deep remission had at least 
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one FC measurement over 50 mg/kg (µg/g). These findings are similar to our 
study in which 65% of patients in stable remission had at least one FC 
measurement over 100 µg/g during the follow-up. De Vos and coworkers 
(2013) suggested that repeated measures of FC, rather than a single FC 
measurement, may help in adjusting therapy in UC patients before clinical 
symptoms emerge. Moreover, the results of our study indicated that 
repeatedly elevated FC levels predict clinical and/or endoscopic relapse, 
whereas mild, transient clinical symptoms seem to have no correlation with 
disease outcome. It is also noteworthy that inflammation is only one 
component of IBD. Symptomatic IBD patients who have normal biomarkers, 
should not simply be labeled as having IBS without further consideration. 
Patients may have symptoms due to noninflammatory mechanical disease 
such as bile salt malabsorption, fibrotic strictures, or adhesions.  
Nevertheless, patients with constantly elevated FC and ongoing clinical 
symptoms are the ones who benefit most from a close follow-up in clinical 
practice. More importantly, repeated measurements of FC appear to be a 
useful noninvasive tool for monitoring patients without endoscopy after 
cessation of TNFα-blocking therapy, as the STORI trial has already indicated. 
The optimal interval for measuring FC has not yet been determined. FC levels 
measured frequently, as often as every 4 weeks, could be the optimal 
approach for predicting relapse, but thiswarrants further research. Based on 
recent studies, restart of treatment would be possible only by documenting 
repeatedly elevated FC levels during follow-up; however, the endoscopic 
assessment of disease activity is currently recommended. Suggested follow-
up strategies after cessation of TNFα-blocking therapy are presented in 
Figure 5.  
 
 
4 Study limitations 
 
These studies have some limitations. The patient groups were heterogeneous 
in all four studies, with both CD and UC patients included regardless of 
localization, behavior, or duration of disease, and therefore, the number of 
patients in the subgroups remained fairly low. In addition, the induction 
doses of both IFX and ADA varied, especially at the beginning of the study 
period, due to local variation in protocols. In Studies III and IV, only patients 
who had responded to TNF-blocking therapy sufficiently to continue with 
scheduled maintenance therapy for at least 11 months were included. This 
may overestimate the efficacy of biological therapies due to endoscopy-based 
case selection. Moreover, the study population in Study II included only 
those maintenance therapy patients who underwent ileocolonoscopy during 
the study period. Although the SES-CD is a validated score for assessment of 
endoscopic activity in CD, no validated cut-offs for endoscopic remission or 
relapse are available. For remission, we used the suggested SES-CD score of 
0–2 published only as an abstract (Moskovitz et al. 2007). In patients with 
UC, an endoscopic Mayo score of 0–1 was defined as a remission, making it 
possible that some patients with UC had very mild endoscopic activity at 
baseline. However, we believe that inclusion of a low baseline FC value as 
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another criterion of remission in Studies II, III, and IV ruled out patients 
with notable inflammatory activity. Additionally, as the data were gathered 
retrospectively in Study II, clinical disease activity was assessed by the PGA 
rather than being based on any validated score.  Furthermore, both clinical 
and endoscopic scoring was performed by several (albeit experienced) 
gastroenterologists, making some interobserver variability in the scoring 
system possible. Unfortunately, rescoring of the endoscopies was not 
possible. However, strength of our studies is that the disease activity 
surveillance included ileocolonoscopies with histological biopsy specimens, 
which were not performed in previous studies. During this study period 
analysis of FC samples was centralized at one laboratory, eliminating 
differences in the analysis process. In Study IV, more concise intervals for 
follow-up samples would have increased accuracy, but would have been more 
inconvenient for the patients. Thus, several patients failed to provide stool 
samples according to the study protocol. Despite the above-mentioned 
limitations, our studies reflect well the situation in clinical practice. 
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Figure 5.  Treatment algorithm. 
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CONCLUSIONS 
In the era of TNFα-blocking therapy, MH and even DR have been suggested 
as new therapeutic targets in both CD and UC. Recent studies have indicated 
that DR may be achieved in roughly half of IBD patients on TNFα-blocking 
maintenance therapy, resulting in more favorable treatment outcomes. 
However, considering the potential side-effects and economic issues 
associated with long-term immunosuppressive therapy with TNFα-blocking 
agents, the possibility of discontinuing therapy should be evaluated at least 
once after achieving DR.  
 
At present, no widely accepted recommendations for discontinuing TNFα-
blocking therapy are available. Based on the results of our study, only for 
about half of patients in DR were candidates for discontinuation of TNF-
blocking medication for various reasons. Nevertheless, up to 67% of IBD 
patients in DR at the time of cessation of TNFα-blocking therapy remained in 
clinical remission during the 12-month follow-up, and moreover, the 
majority of these patients also remained in endoscopic remission. Therefore, 
withdrawal of therapy could be considered in IBD patients in DR even after 
one-year treatment. Reassuringly, in case of a relapse, the response to restart 
of TNFα-blocking therapy seems to be effective and well-tolerated. 
 
To evaluate treatment response and possible relapse during maintenance 
therapy or after discontinuation of TNFα-blocking therapy, FC seems to be a 
reliable surrogate marker to replace endoscopic assessment. A normal FC 
after induction with TNFα-blocking agents predicts sustained remission in 
the majority of patients with active luminal disease receiving scheduled 
treatment.  However, an objective cut-off value for treatment response and 
relapse risk is to some extent still undefined. To predict IBD relapse and 
identify patients requiring a close follow-up in clinical practice, FC seems to 
be a useful surrogate marker, as it increases and remains elevated as early as 
6 months before symptomatic relapse. FC measurements should therefore be 
included in monitoring IBD patient’s treatment response in everyday clinical 
practice.  
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FINNISH SUMMARY 
Yhteenveto 
 
Tausta 
Krooniset tulehdukselliset suolistosairaudet, Crohnin tauti ja haavainen 
paksusuolitulehdus, ovat tavallisimmin noin 20–35-vuotiaana ilmaantuvia 
sairauksia, joiden vaikeimpia tautimuotoja voidaan hoitaa ns. biologisilla 
lääkkeillä eli esim. tuumorinekroositekijä α:n vasta-aineilla (anti-TNF). 
Näihin lääkkeisiin liittyy kuitenkin sekä haittavaikutuksia että merkittäviä 
kustannuksia. Tulehduksellisten suolistosairauksien kroonisen luonteen 
vuoksi biologinen lääkehoito voi muodostua pitkäaikaiseksi, eikä hoidon 
lopettamiselle ole laadittu kansainvälisiä tai kansallisia ohjeita. Ulosteesta 
mitattava merkkiaine, kalprotektiini, on käyttökelpoinen menetelmä taudin 
aktiivisuuden määrittämisessä ja seurannassa. Kalprotektiinin asemasta 
limakalvoparanemisen ennustajana biologisen lääkehoidon aikana ja taudin 
uusiutumisen ennustajana hoidon lopettamisen jälkeen on rajallisesti tietoa. 
 
Potilaat ja menetelmät 
Väitöskirjatyö koostuu neljästä osatyöstä (I-IV). Anti-TNF-ylläpitohoidon 
tehon selvittämiseksi analysoitiin takautuvasti 252 biologista hoitoa saaneen 
tulehduksellista suolistosairautta sairastavan potilaan tiedot kahdeksassa 
tutkimuskeskuksessa (II). Biologisen lääkehoidon lopettamista sekä sen 
tehoa ja siedettävyyttä lääkehoidon uudelleen aloittamisen jälkeen 
selvitettiin seurantatutkimuksessa vuosina 2010–2013 (III: 52 potilasta). 
Lisäksi selvitettiin ulosteen kalprotektiinin kykyä ennustaa pitkäaikaista 
limakalvoparanemista anti-TNF-hoitoa saaneilla potilailla (I: 60 potilasta) ja 
sen kykyä ennustaa taudin uusiutumista anti-TNF-hoidon lopettamisen 
jälkeen (IV: 52 potilasta). 
 
Tulokset 
252 anti-TNF-hoitoa saaneesta potilaasta kaksi kolmasosaa saavutti kliinisen 
ja noin puolet syvän remission lähes vuoden jatkuneen ylläpitohoidon 
aikana; haavaista paksusuolitulehdusta sairastavat hieman useammin kuin 
Crohnin tautia sairastavat. Merkittävä osa saavutti myös histologisen 
remission. Vuosi anti-TNF-hoidon lopettamisen jälkeen 67 % potilaista oli 
kliinisessä remissiossa ja hoidon uudelleen aloittaminen johti kliiniseen 
remissioon 93 %:lla potilaista. Normaali ulosteen kalprotektiini kolme 
kuukautta hoidon aloittamisen jälkeen näyttää ennustavan suotuisaa 
hoitovastetta vuoden jatkuneen hoidon jälkeen. Toistuvasti mitattu, 
kohonnut ulosteen kalprotektiinitaso anti-TNF-hoidon lopettamisen jälkeen 
ennustaa relapsia. 
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Päätelmät 
Syvä remissio on saavutettavissa noin puolella anti-TNF-ylläpitohoitoa 
saavista potilaista. Biologinen lääkehoito on turvallista lopettaa vuoden 
kuluttua niiltä Crohnin tautia tai haavaista paksusuolitulehdusta sairastavilta 
potilailta, jotka ovat syvässä remissiossa. Hoidon uudelleen aloitus on sekä 
tehokasta että turvallista. Ulosteen kalprotektiinin määritys biologisen 
lääkehoidon aikana sekä lääkehoidon lopettamisen jälkeen optimoi hoitoa ja 
sairauden seurantaa.  
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